Trial Protocol
A Phase II, Randomized, Double -Blind, Placebo -Controlled 
Study of Bermekimab in Patients with Moderate to Severe 
Atopic Dermatitis
SPONSOR
XBiotech USA Inc
22January 2020
[STUDY_ID_REMOVED]
Page 2of 61TABLE OF CONTENTS
Basic Information ...................................................................................................................................... 4
Abbreviations ........................................................................................................................................... 15
1. BACKGROUND ........................................................................................................................... 16
1.1 OVERVIEW ............................................................................................................................................. 16
1.2 RATIONALE ............................................................................................................................................ 17
2. INVESTIGATIONAL PRODUCT ........................................................................................... 19
2.1 ACTIVE	INGREDIENT,	PHARMACOLOGIC	CLASS,	STRUCTURE..................................... 19
2.2 DRUG	PRODUCT	(BERMEKIMAB	200	MG/ML)	DESCRIPTION ...................................... 20
2.3 STORAGE ................................................................................................................................................. 20
2.4 STABILITY .............................................................................................................................................. 20
2.5 DESIGNATED	INDIV IDUAL	FOR	DRUG	ADMIN ISTRATION ............................................. 20
2.6 METHOD	OF	ADMINISTRATION .................................................................................................. 21
2.7 AGENT	ORDERING .............................................................................................................................. 22
2.8 POTENTIAL	DRUG	INTERACTIONS ............................................................................................ 22
2.9CONCOMITANT	THERAPY .............................................................................................................. 22
2.9.1 Antihistamine/NSAID Use ....................................................................................... 22
2.9.2 Required Treatment .................................................................................................. 22
2.9.3 Permitted Medications and Procedures .................................................................... 23
2.10 PROHIBITED	MEDICATIONS	AND	PROCEDURES ................................................................ 23
2.11 RESCUE	TREATMENT ....................................................................................................................... 24
3. STUDY DESIGN AND OBJECTIVES .................................................................................... 24
4. ELIGIBILITY CRITERIA ......................................................................................................... 29
4.1 INCLUSION	CRITERIA ....................................................................................................................... 29
4.2 EXCLUSION	CRITERIA ...................................................................................................................... 30
5. TREATME NT PLAN .................................................................................................................. 32
5.2 STUDY	CALENDARS ........................................................................................................................... 39
5.2.1 Placebo- controlled Period ........................................................................................ 39
5.2.2 Blinded Active Dosing Period .................................................................................. 40
5.2.3 Follow -up Period ...................................................................................................... 41
5.3 DISCONTINUATION	OF	THERAPY .............................................................................................. 42
5.4 TRIAL	STOPPING	RULES ................................................................................................................. 42
5.5 EMERGENCY	UNBLINDING ............................................................................................................ 42
6. CORRELATIVE STUDIES ....................................................................................................... 43
6.1 PHARMACOKINETICS	(PK)	SAMPLE	COLLECTION ............................................................. 43
7. ASSESSMENT OF SAFETY ..................................................................................................... 43
8. STUDY VARIABLES .................................................................................................................. 44
8.1 DEMOGRAPHI C	AND	DISEASE	CHARACTERISTICS ............................................................ 44
8.2 STUDY	ASSESSMENTS ...................................................................................................................... 44
9. ADVERSE EVENTS .................................................................................................................... 46
9.1 DEFINITION	O F	ADVERSE	EVENT	(AE) ................................................................................... 46
9.2 DEFINITION	OF	SERIOUS	ADVERSE	EVENT	(SAE) ............................................................. 46
9.3 RECORDING	OF	ADVERSE	EVENTS ............................................................................................ 47
9.4 EVALUATING	ADVERSE	EVENTS ................................................................................................ .47
9.5 ASSESSMENT	OF	CAUSALITY ........................................................................................................ 48
Page 3of 619.6 REPORTING	REQUIREMENTS ....................................................................................................... 48
9.7 REFERENCE	SAFETY	INFORMATION:	POTENTIAL	ADVERSE	REACTIONS ............48
10. STATISTICAL PLAN ............................................................................................................ 50
10.1 DETERMINATION	OF	SAMPLE	SIZE ........................................................................................... 50
10.2 RANDOMIZATION ............................................................................................................................... 50
10.3 ANALYSIS	SETS .................................................................................................................................... 50
10.4 PATIENT	DISPOSITION .................................................................................................................... 51
10.5 STATISTICAL	METHODS .................................................................................................................. 51
10.5.1 Demography and Baseline Characteristics .......................................................... 51
10.5.2 Safety Analysis .................................................................................................... 51
10.5.2.1 Analysis	of	Adverse	Events ............................................................................................................ 51
10.5.2.2 Other	Safety .......................................................................................................................................... 52
10.5.3 Efficacy Analysis ................................................................................................. 52
10.5.3.1 Primary	Efficacy	Analysis ............................................................................................................... 52
10.5.3.2 Secondary	Efficacy	Analyses ......................................................................................................... 53
10.5.4 Treatment Exposure ............................................................................................. 53
10.5.5 Pharmacokinetic (PK) and Pharmacodynamics (PD) Analysis: .......................... 53
11. STUDY MANAGEMENT AND ADMINISTRATION .................................................. 54
11.1 ETHICAL	CONDUCT	OF	STUDY	(GCP) ....................................................................................... 54
11.2 IRB	AND	ETHICS	COMMITTEE	APPROVAL ............................................................................. 54
11.3 PROTOCOL	MODIFICATIONS ......................................................................................................... 54
11.4 SUBJECT	INFORMATION	AND	CONSENT ................................................................................ 55
11.5 DATA	PROTECTION	AND	CONFIDENTIALITY ....................................................................... 55
11.6 STUDY	REPORT	AND	PUBLICATIONS ....................................................................................... 56
11.7 STUDY	FILES	AND	RETENTION	OF	RECORDS ...................................................................... 56
11.8 CASE	REPORT	FORMS ....................................................................................................................... 56
11.9 DRUG	ACCOUNTABILITY ................................................................................................................. 57
11.10 AUDITS	AND	INSPECTIONS ........................................................................................................... 58
11.11 ACCESS	TO	INFORMATION	FOR	MONITORING .................................................................... 58
11.12 STUDY	DISCONTINUATION ............................................................................................................ 59
REFERENCES ........................................................................................................................................ 60
Page 4of 61Basic Information
STUDY TITLE: A Phase II, Randomized, Double -Blind, Placebo- Controlled Study of Bermekimab in 
Patients with Moderate to Severe Atopic Dermatitis
INVESTIGATIONAL PRODUCT: Bermekimab 
IND Number : 112,459
PROTOCOL NUMBER: 2019-PT046
PROTOCOL VERSION / DATE: 2.0/ 22January 2020
SPONSOR: XBiotech USA, Inc. 
5217 Winnebago Ln.
Austin, Texas 78744 U.S.A.
Phone: +1 ( 512) 386-2900
SPONSOR’S MEDICAL OFFICER:
Phone: +
STUDY CHAIR
Phone: +
PPD
PPD
PPD
PPD
Page 5of 61Investigator/Sponsor Signatures
STUDY TITLE: A Phase II, Randomized, Double -Blind, Placebo -Controlled  Study of Bermekimab in 
Patients with Moderate to Severe Atopic Dermatitis
PROTOCOL VERSION / DATE: 2.0/ 22January 2020
STUDY PRINCIPAL INVESTIGATOR SIGNATURE: I have read the protocol and appendices. 
I understand the contents and intend to comply fully with all requirements and the applicable current local 
and international regulations and guidelines. No changes will be made without formal authorization by 
XBiotech USA, Inc., in the form of a protocol amendment.
INVESTIGATOR SIGNATURE:
_____________________________________________ 
Printed name of Investigator 
_____________________________________________ 
Signature 
_____________________________________________ 
Date 
SPONSOR SIGNATURE: 
XBiotech USA, Inc.
____________________________________________ 
Printed Name
____________________________________________ 
Signature
____________________________________________ 
Date
Page 6of 61Clinical Protocol Synopsis
STUDY TITLE:  A Phase II, Randomized, Double -Blind, Placebo- Controlled  Study of Bermekimab in 
Patients with Moderate to Severe Atopic Dermatitis
Sponsor:  
XBiotech USA, Inc.
Study Chair :  
Seth Forman , M.D.
Sample Size:
Approximately 90 patients will be enrolled in the US
Approximate Duration:   
The duration of subject participation in the randomized, double -blind, placebo -controlled portion of the 
trial is approximately 40 weeks: including a screening period of up to 30 days, a 32 -week treatment period,
and 4- week follow -up period. 
Study Endpoints :
Primary Endpoint(s):
Percentage of patients achieving Eczema Area and Severity Index -75 (EASI -75) ( ≥75% 
improvement from baseline) at week 16 .
Secondary Endpoints:
Percentage of patients achieving ≥4-point improvement (reduction) in the weekly average peak 
daily Pruritus Numeric Rating Scale (NRS) score from baseline to weeks 4, 8, 12, 16, and 32 in 
patients with baseline score ≥4.*
Percentage of patients achieving ≥4-point im provement (reduction) in the weekly average overall 
Pruritus Numeric Rating (NRS) from baseline to weeks 4, 8, 12 16, and 32in patients with baseline 
score ≥4.* 
Percentage of patients achieving ≥4-point improvement (reduction) in the weekly average peak 
daily Pain Numeric Rating Scale (NRS) score from baseline to weeks 4, 8, 12, 16, and 32 in patients 
with baseline score ≥4.*
Page 7of 61Percentage of patients achieving ≥4-point im provement (reduction) in the weekly average overall 
Pain Numeric Rating (NRS) from baseline to weeks 4, 8, 12, 16, and 32 in patients with baseline 
score ≥4.*
Percentage of patients achieving EASI -75 (≥75% improvement in Eczema Area and Severity Index 
Score [EASI] from baseline) at weeks 4, 8 , 12, and 32 .*
Percentage of patients achieving an Investigators Global Assessment (IGA) score of 0 or 1 (on a 5-
point scale) and a reduction in this measure from baseline of at least 2 points at week 16.
Percentage of patients achieving EASI -90 (≥90% improvement in Eczema Area and Severity Index 
Score [EASI] from baseline) at weeks 12 ,16, and 32 .*
Change in Dermatology Life Quality Index (DLQI) from baseline to weeks 8, 12, 16 , and 32. *
Change in Hospital Anxiety Depression Scale (HADS) (Anxiety) from baseline to weeks 8, 12, 16 , 
and 32.*
Change in Hospital Anxiety Depression Scale (HA DS) (Depression) from baseline to weeks 8, 12 , 
16, and 32. *
Change in Patient Oriented Eczema Measure (POEM) Scores from baseline to weeks 8, 12, 16, and 
32.*
Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to weeks 8, 12, 16, and 
32.*
Change in Global Individual Signs Score (GISS) from baseline to weeks 8, 12 , 16, and 32.*
Exploratory Endpoints:
Percentage of patients achieving an IGA score 0 or 1 (on a 5-point scale) and a reduction in this 
measure from baseline of at least 2 points at week 12.
Change in Eczema Area and Severity Index Score (EASI) from baseline to weeks 8, 12, 16, and 
32.
Change from baseline to week 4 in Dermatology Life Quality Index (DLQI).
Patients (%) achieving 50% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, a nd 32.*
Patients (%) achieving 75% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, and 32.*
Patients (%) achieving 90% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, and 32.*
Change from baseline to week 8, 12, 16, and 32 in percent Body Surface Area (BSA).*
Page 8of 61Safety Endpoints: 
Incidence of skin infection treatment -emergent adverse events (TEAEs) requiring systemic 
treatment from baseline through week 16 and 32.
Incidence of treatment -emergent serious adverse events (TESAEs) from baseline through week 16 
and 32.
Incidence of TEAEs leading to treatment discontinuation from baseline through week 16 and 32.
*Each listed time point (in weeks) will be measured separately and treated as an individual endpoint. 
Page 9of 61Trial Design:   
This is a phase II, randomized, double -blind, placebo -controlled study to further establish the efficacy and 
safety and explore dose effects forbermekimab monotherapy in adults with moderate tosevere Atopic 
Dermatitis (AD) . Patients will be assessed for study eligibility at the initial screening visit after providing 
informed consent. Thirty days are allowed in the screening window to complete all screening procedures 
and randomize the subject. During the screening period, certain treatments will be washed out, as 
applicable, according to eligibility requirements. Patients who fail initially may be re-screened once based
ontheinvestigator discretion butonly ifinclusion criteria aremetattime ofre-screening.
The study is approximately 40 weeks (30 day screening period, 32-week treatment period and a 4-week 
follow -up period) for all subjects.
The primary efficacy endpoint is the percentage of patients achieving ≥75% improvement from basel ine 
in EASI score at week 16. The EASI is a validated measure used in clinical practice and clinical trials to 
assess the severity and extent of AD. Secondary measures will include Pruritus NRS, Pain NRS, 
SCORAD, POEM, GISS, DLQI, HADS, BSA and IGA. 
Patients who meet the eligibility criteria at screening will be randomized in a 1:1:1 ratio to one of two
treatment arms or placebo :
Arm 1: 800 mg of bermekimab + placebo loading dose (2mL SC injection containing 400 mg of 
berm ekimab and one 2mL SC injecti on of placebo) at week 0 followed by weekly (qw) 
subcutaneous (SC) injections of 400 mg bermekimab through week 3 1
Arm 2: 800 mg loading dose of bermekimab (2 x 400 mg SC injections) at week 0 followed by 
subcutaneous (SC) injections of 400 mg bermekimab every other week (q2w) alternating with 
matching placebo q2w through week 3 1.
Arm 3: 4mL loading dose of placebo (2 x 2mL SC injections) at week 0 followed by weekly 
placebo injections from week 1through week 15. Patients in Arm 3 will begin to receive weekly 
(qw) blinded subcutaneous (SC) injections of 400 mg bermekimab beginning at week 16 through 
week 31.
In order to maintain blinding, all patients will receive two injections at week 0and 16, followed by weekly 
injections from week 1 to 31.Additio nally, at least one qualified individual will be designated at each 
study site to perform all preparation and injection of the investigational product. The designated 
Page 10of 61injector(s) should have no other contact with the participant during the study, should not discuss the 
participant’s treatment with the participant, participant’s caregiver, or other site personnel at any time, and 
will not be permitted to review the participant’s medical records, questionnaires, or the electronic CRF 
prior to each injection. The designated injector(s) should be documented in the source documents at each 
visit.
Study treatment willbeadministered weekly inthe clinic for31weeks with weekly office visits for 32 
weeks. Patients willremain atthestudy siteforaminimum of 30 minutes (+/ -10 minutes) after injections 
at weeks 0, 1, 2, 16, 17 and 18 injections for safety monitoring. 
During the 32-week treatment period, patients will attend weekly clinical study visits. Clinical 
assessments, collection of samples for bermek imab concentrations, and safety testing will be performed 
at specified clinic visits.   After completion of the 36 -week study period, data will be locked and analyzed 
for safety and efficacy endpoints for all arms. In addition to the analyses that will be p erformed following 
the formal database lock at the end of the study at Week 36, an additional database lock may be performed 
at Week 16, and interim analyses utilizing unblinded efficacy data available as the study progresses, may 
also be conducted to help plan potential future development activities. An internal interim analysis 
committee (IAC) will be established to review the interim data and formulate recommended 
decisions/actions. The IAC will consist of at least a clinician and a statistician (neith er of whom are 
involved in study conduct or compound development), one of whom will chair the committee, and may 
also include other members as required by the nature of the IAs. Details will be provided in a separate 
IAC charter, which will define the organization and roles and responsibilities of the committee, possible 
recommendations or requests, and the communication process following IA reviews. Results from the 
Week 16 database lock and/or interim analyses will not be disseminated to investigators or subjects 
participating in the study.  In addition, results of the interim analyses will not be disseminated to 
individuals associated with the conduct of the study.
Patients will be monitored at a follow up visit (visit 34/week 36) for safety and clinical assessments after 
completing the 32 week treatment period. 
Procedures and Assessments:
Multiple parameters will be collected during the study to evaluate the efficacy of bermekimab, including 
measures of AD severity, and patient -reported measures of AD symptoms and quality of life.
Page 11of 61The safety of bermekimab in this population will be assessed by evaluating treatment emergent adverse 
events (TEAEs), vital signs, thorough physical examination, detailed medical history, electrocardiograms 
(ECGs), and clinical laboratory testing. Concomitant medications and procedures will be collected from 
time of informed consent to the end of study.  Safety  data will be reviewed on anongoing basis by the 
sponsor.  
Blood samples will be collected for laboratory testing including chemistry, hematology, inflammation 
markers, bermekimab concentration (PK), PD marker(s), anti -drug antibody (ADA) and research analysis 
etc. at pre -determined time points.  
Figure 1. Study Flow Diagram
Inclusion Criteria: 
No waivers/exemptions will be granted for protocol inclusion/exclusion criteria.
Subjects are inclu ded in the study if they meet all of the following criteria:
Written informed consent provided by the patient.
Male or female, at least 18 years.
Willing and able to attend all clinic visits and comply with study -related procedures .
Is able to understand and complete study -related questionnaires .
Chronic a topic dermatitis present for at least 3 years.
EASI score ≥16 at screening and baseline visits .
IGA score ≥3 at screening and baseline visits .BaselineEndpoint  
Assessment
Visit (V) V1 V33
Week (W) W0 W32
Day (D) D0 D224W1 to W31 W36
D7 to D2 17 D252Screen ing Treatment Period 
Follow-up 
Weekly Dosing
V2 to V32 V34
D -30 to -1 
Page 12of 61Baseline pruritis numerical rating scale average score for maximum intensity of at least 3, based 
on the average of daily pruritis numerical rating scale scores for maximum itch intensity reported 
during the 7 days prior to randomization.
Has applied a stable dose of topical moisturizer twice daily for at least 7 consecutive days 
immediate ly prior to the baseline visit andis willing to continue this regimen on a daily basis for 
the duration of the study.
≥10% body surface area (BSA) of AD involvement at screening and baseline vi sits.
Documented recent history (within 6 months prior to screening) of inadequate respons e to treatment 
with topical medications, or patients for whom topical treatments are medically inadvisable 
(because of important side effects or safety risks).
a)Inadequate response is defined as failure to achieve and maintain remission or a low 
disease activity state (comparable to an IGA score of 0-2), despite treatment with a daily  
regimen of topical corticosteroids of medium to higher potency (with or without topical 
calcineurin inhibitors as appropriate ), applied for at least 28 days or for the maxim um 
duration recommended by the product prescribing information, whichever is shorter.
b)Patients with documented systemic treatment for atopic dermatitis in the preceding 6 
months are also considered to be inadequate responders to topical treatments and are 
potentially eligible for treatment with bermekimab , after appropriate washout.
c)Important side effects or risks are those that outweigh the potential treatment benefits, and 
include: intolerance to treatment, hypersensitivity reactions, significant skin atr ophy, and 
adverse systemic effects.
d)Acceptable documentation includes contemporaneous chart notes that record topical 
medication prescription and treatment outcome, or investigator documentation based on 
communication with the patient’s treating physician.
Exclusion Criteria:
Subjects with ANY of the following will be excluded from the study:
Age below 18 years as the current study is evaluating bermekimab in adult patients only.
Subject has been treated for AD with any investigational drug of chemical or biologic nature within 
a minimum of 30 days or 5 half -lives (whichever is longer) of the drug prior to baseline .
Treatment with bermekimab at any time in the past.
Treatment with immunosuppressive/immunomodulatory drugs or phototherapy for atopic
Page 13of 61dermatiti s within 4 weeks of baseline, or any condition that, in the opinion of the investigator, is 
likely to require such treatment(s) during the first 4 weeks of study treatment .
Treatment with topical corticosteroids or topical calcineurin inhibitors for the treatment of AD 
within 14 days prior to baseline ].
Treatment with biologics as follows:
a) Any cell -depleting agents including , but not limited to, rituximab, within 5 half -lives (if known) 
or 30 days prior to baseline visit, or until lymphocyte count returns to normal, whichever is longer .
b)Other biologics: within 5 half -lives (if known) or 30days prior to baseline visit, whichever is 
longe r
Initiation of treatment of atopic dermatitis with prescription moisturizers or moisturizers containing 
additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the 
screening period (patients may continue to use stable doses of such moisturizers if initiated before 
the screening visit) .
Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the screening
visit.
Planned or anticipated use of any prohibited medications and procedures during study treatment .
Treatment with a live (attenuated) vaccine within 30 days prior to the scree ning visit.
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals,
antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to the baseline visit, orsuperficial 
skin infections within 1 week prior to the baseline visit. NOTE: patients may be rescreened after 
infection resolves .
Known or suspected history of immunosuppression, including history of invasive opportunistic
infections (e.g., tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis,
aspergillosis) despite infection resolution; or unusually frequent, recurrent, or prolonged infections, 
per investigator judgment .
History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening .
Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody at the
screening visit .
At baseline, presence of any conditions listed as criteria for study drug discontinuation .
Presence of skin comorbidities that may interfere with study assessments .
History of malignancy within 5 years before the screening visit, except completely treated in situ
carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal
cell carcinoma of the skin .
Page 14of 61Severe concomitant illness(es) that, in the investigator ’s judgment, would adversely affect the 
patient ’s participa tion in the study. Examples include, but are not limited to, patients with short life 
expectancy, patients with uncontrolled diabetes (HbA1c ≥ 9%),  patients with cardiovascular 
conditions (eg, stage III or IV cardiac failure according to the New York Heart Association 
classification), severe renal conditions (eg, patients on dialysis), hepato -biliary conditions (eg, 
Child -Pugh class B or C), neurological conditions (eg, demyelinating diseases), active major 
autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other 
severe endocrinological, gastrointestinal, metabolic, pulmonary or lymphatic diseases. The specific 
justification forpatients excluded under this criterion will be noted in study documents (chart notes, 
case report forms [CRFs], etc.) .
Planned or anticipated major surgical procedure during the patient’s participation in this study .
Patient or immediate family member is part of the current clinical investigational team .
Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the
study .
Women unwilling to use adequate birth control, if of reproductive potential and sexually 
active. Adequate birth control is defined as consistent practice of an effective and accepted method 
of contraception throughout the duration of the study and for 120 days after the last dose of study  
drug. These methods include oral contraceptives (stable use for more than 3 months before 
Screening), intrauterine device (IUD), hormonal contraceptives such as Depo -Provera (stable use 
for m ore than 3 m onths before Screening), Implanon implants (stable use for more than 3 months 
before Screening), double barrier contraception such as condom or diaphragm used with 
contraceptive sponge, foam, or jelly. For men participating in the study, unwillingness of sexual 
partner to use any of the above contraception methods.
History of severe allergic or anaphylactic reactions to monoclonal antibodies.
Any other medical or psychological condition (including relevant laboratory abnormalities at
screening) that, in the opinion the investigator, may suggest a new and/or insufficiently understood 
disease, may present an unreasonable risk to the study patient as a result of his/her participation in 
the study, may make patient’s participation unreliable, or may interfere with study assessments. 
The specific justification for patients excluded under this criterion will be noted in study documents 
(chart notes, case report forms, etc.)
Page 15of 61Abbreviations
ADA Anti-Drug Antibody
AD Atopic Dermatitis
AE Adverse event
ALT Alanine aminotransferase (ALT, SGPT)
PT/aPTT Prothrombin Time/Activated Partial Thromboplastin Time
ALP Alkaline phosphate
BMI Body  mass index
BP Blood pressure
BSA Body  Surface Area
CBC Com plete blood counts
CI Confidence interval
CH Heavy chain constant region
CL Light chain constant region
eCRF Electronic Case report form
CRA Clinical Research Associate
CRP C-Reactive Protein
CTCAE Common terminology criteria for adverse events
DLQI Derm atology Life Quality Index
EASI Eczem a Area and Severity Index Score
EC Ethics Committee
ECG/E KG Electrocardiogram
ELISA Enzyme -linked immunosorbent assay
GISS Globa l Individual Signs Score
GCP Good clinical practice
HADS Hospital Anxiety Depression Scale
HbA1c Hemoglobin A1c
HBsAg Hepatitis B surface antigen
HIV Human immunodeficiency virus
ICF Informed Consent Form
IFN-  Interferon Gamma
IGA Investigator’s Global Assessment
IGRA Interferon Gamma Release Assay
IgG Immunoglobulin G
IL-6 Interleukin -6
IL-1  Interleukin -1 
IL-1 Interleukin -1 
IL-1 RA Interleukin -1 receptor antagonist
IRB Institutional review board
NRS Numerical Rating Scale
NSAID Non-Steroidal Anti -Inflammatory Drug
PD Pharm acody namics pI Isoelectric Point
PK Pharm acokinetics
POEM Patient Oriented Eczema Measure
SAE Serious Adverse Event
SAF Safety analysis set
SAP Statistical analysis plan
SAS Statistical analysis software
SCORAD Severity Scoring of Atopic Dermatitis
TB Tuberculosis
UV Ultraviolet
VAS Visual Analogue Scale
WOCBP Wom en of childbearing potential
Page 16of 611. BACKGROUND
1.1 OVERVIEW
XBiotech USA, Inc. has developed a True Human recombinant IgG1 monoclonal antibody, bermekimab , 
that binds the cytokine interleukin -1alpha (IL-1)with high affinity and is an effective blocker of IL-1
biological activity. IL-1is a key mediator of sterile inflammatory responses and has been implicated in 
the pathology of advanced cancer, cardiovascular disease, and rheumatologic disease. Clinical evidence 
generated to date suggests that targeting IL-1may be an effective means of undermining the inflamm atory 
process that drives a wide array of diseases, including dermatologic conditions.
The active ingredient in the drug product bermekimab is MABp1, a recombinant human IgG1 monoclonal 
antibody specific for human interleukin -1(IL-1). The entire MABp1 heavy and light chain sequences 
are ident ical to those found in naturally -occurring human IgG1, with the light and heavy chain variable 
regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obta ined 
from a healthy individual. No in vitro affinity matur ation or m odifications have been m ade to im prove its 
natural binding affinity (211 +/ -31 pM). We believe that a true human antibody should be effectively non -
immunogenic in humans and thus exhibit optimal activity and pharmacokinetics.  
XBiotech has conducted 13clinical studies to date using the bermekimab antibody.  These studies have 
been conducted in a wide range of therapeutic areas, from cancer to healthy volunteers, and have included 
severa l different dose levels and dosing schedules. Both intravenous and subcutaneous formulations have 
been explored for safety and evidence of efficacy. Five Phase II studies sponsored by XBiotech have been 
completed in dermatologic indications (psoriasis [NCT 01384630], acne vulgaris [[STUDY_ID_REMOVED]] ,
pyoderma gangrenosum [[STUDY_ID_REMOVED]] , atopic dermatitis [[STUDY_ID_REMOVED]] , and hidradenitis suppurativa
[[STUDY_ID_REMOVED] ]), as well as one investigator sponsored study in Hidradenitis Suppurativai,ii,iii.
Subjects with moderate to severe psoriasis experienced a rapid reduction in their psoriasis area and severity 
index (PASI), and subjects with acne vulgaris experienced reductions of inflammatory lesion counts, as 
well as reduced hospital anxiety and depres sion scores (HADS). Similarly, when MABp1 was used in 
patients with pyoderma gangrenosum, there was a marked improvement in lesions over a short period of 
time. In the two most recent studies forhidradenitis suppurativa and atopic dermatitis , statistically 
significant improvement was seen for nearly every efficacy endpoint by the end of the study.
Page 17of 61Results from atopic dermatitis study showed that bermekimab appeared to be safe, well tolerated, and active 
at reducing the severity of atopic dermatitis, including reducing itch and pain. This study was a phase II, 
open label, dose escalation study of bermekimab in subjects with moderate to severe atopic dermatitis. 
Thirty- eight patients across 9 clinical sites in two treatment groups received one of two subcutaneous (SC) 
doses: a low (200 mg, n=10) or high (400 mg, n=28) dose of bermekimab once weekly for either a 4 or 8-
week treatment regimen, respectively. Safety was assessed by pre- and post-treatment measurements of 
vital signs, clinical laboratory assessments (blood chem istry, urinalysis, hematology), allergic reaction 
monitoring, and adverse event monitoring. Efficacy was assessed by change in EASI, IGA, NRS, 
SCORAD, POEM, DLQI, and GISS from  baseline to visit 9. The primary measure of efficacy was the 
EASI. In the study , 39% of high dose patients achieved 75% improvement in EASI score (EASI -75) after 
4 weeks of therapy and 75% of patients achieved EASI -75 at week 8. Of note, participants were not allowed 
to use concomitant topical corticosteroids during the study and thus these improvements were m ost likely 
due to the study drug alone.
While clinically and statistically significant improvement was seen for all clinical endpoints in the high 
dose group, also notable was the speed, magnitude, and trajectory of responses seen. In the high dose group, 
for example, after only four weeks of treatment, 61% of patients achieved a 4-point improvement in the 
Pruritus Numerical Rating Scale (NRS) for overall itch; and 75% of patients achieved a 4-point 
improvement by week 8.For the Pruritus Numerical Rating Scale (NRS) –worst moment itch after only 
four weeks of treatment, 63% of patients achieved a 4-point improvement and 78% of patients achieved a 
4-point improvement by week 8. Furthermore, 80% of patients achieved a 4-point improvement in the 
Numerical Rating Scale (NRS) for pain by week 8.
Overall, bermekimab appeared safe, well tolerated, and showed significant therapeutic activity in most 
subjects. In all of these trials, there were few adverse events, most of which were grade 1 (mild ).
1.2 RATIONALE
Atopic dermatitis (AD) ,is an inflammatory skin disease affecting 1-20% of the adult population. Chronic 
eczema in AD and associated pruritus can be a significant cause of morbidity and can impact quality of life. 
Disease pathogenesis is complex but ultimately converges on a pathological inflammatory process that 
disrupts the protective barrier function of the skin. 
Page 18of 61IL-1⍺ plays a key role in the pathophysiology of a wide range of inflammatory skin disordersv.  
Keratinocytes are a maj or reservoir of IL -1⍺and may be a key source of inflammatory stimulus in AD.  IL -
1⍺is present on leukocytes, where its role in leukocyte trafficking and infiltration may represent an essential 
step in the chronic inflammation of AD.  IL-1⍺is a key inducer of matrix metalloproteinases activity whic h 
could be directly involved in the epithelial barrier breakdown in ADvi. Further, in a study by Archer et al, 
IL-1⍺, rather than IL -1β,was not only a fundamental component for inducing chronic skin inflamation, but 
the primary driving forcevii. The study included mice with epidermal birth defects and showed that 
keratinocytes, which constitute approximately 90% of skin cells, secrete aberrant stores of intracellular IL -
1⍺in response to skin injury (e.g. scratching), leading to chronic skin inflammation. Atopic Dermatitis is 
strongly associated with epidermal barrier defects, most commonly caused by mutated copies of the 
filaggrin geneviii. Filaggrin deficiencies are associated with changes in the composition of bacteria living on 
the skin, whereby bacte ria can colonize and infect the skin with greater success thereby exacerbating 
aberrant IL -1⍺secretionix.Neutralizing IL -1⍺activity resolved chronic skin inflammation in this study and 
strongly support edIL-1⍺as a key target for treating atopic dermatitis, along with other inflammatory skin 
disea ses.
Endogenous anti -IL-1α antibodies are present in 5% to 28% of the general populationx,xi,xii,xiii.  No negative 
correlations with disease have been noted for these individuals. To the contrary, the presence of natural 
anti-IL-1α antibodies has been associated with favorable outcomes, both with respect to rheumatoid arthritis 
and ischemic heart disease. Animal studies also indicate that IL-1α loss or antagonism does not result in 
harm. Moreover, the well-tolerated use of other approved biological agents that employ alternative 
strategies to block IL-1 activity suggest that MABp1’s targeting of IL-1α represents a safe treatment 
approach. 
In previous dermatology studies bermekimab was well tolerated and showed impressive therapeutic 
activity. The safety data from XBiotech’s open label studies: PT044 atopic dermatitis and PT045 
hidradenitis suppurativa established good levels of safety and tolerability for 400mg bermekimab (2mL of 
200mg/mL) subcutaneous injections and in both studies no safety signals were identified and no study 
stopping rules were met. 
Page 19of 612. INVESTIGATIONAL PRODUCT
2.1 ACTIVE INGREDIENT, PHARMACOLOGIC CLASS, STRUCTURE
Figure 2: Bermekimab Antibody
The bermekimab primary glycoform has a molecular weight of 148.1 kilodaltons. Like all IgG1 molecules, 
the heavy chains are joined at their hinge regions through two disulfide linkages, and each heavy chain is 
joined to one light chain through one disulfide linkage between their CH 1and CL domains respectively.
The main isoform has a pI of about 9.2 and comprises about 70 -80% of the total isoform population in all 
lots that have been manufactured to date, as determined by capillary isoelectric focusing. The heavy chain 
CH 2domains are glycosylated primarily with the oligosaccharide structure shown in Figure 2, as 
determined by mass spectroscopy of the cleaved glycans. The glycosylated residue (Asn -302 as numbered 
from the N-terminus of bermekimab) has been determined by peptide mappi ng to be in the same highly 
conserved N-linked glycosylation site as found in endogenous IgG1 (Asn -297 according to the generic 
numbering system). Similarly, the primary glycan, commonly referred to as G0F, is the same as that found 
on about 22% of endogenous human IgG moleculesxiv. 
The entire bermekimab heavy and light chain sequences are identical to those found in naturally -occurring 
human IgG1 , with the light and heavy chain variable regions being identical to those originally expressed 
by a peripher al blood B lymphocyte that was obtained from a healthy individual.  
Endogenous anti-IL-1α antibody has been reported in 5% to 28% of healthy serum or plasma 
samplesx,xi
and cord bloodxv.The anti-IL-1α antibodies measured in human plasma are IgG, in particular IgG1, IgG2, 
and IgG4 sublasses . Relatively equal prevalence for these antibody areseen in male and female plasmaxvi.
Binding affinities reported for endogenous anti -IL-1α antibodies, ranging from 4 to 16 pM, are comparable 
to that for 
bermekima b, the specification for which is 22 to 260 pM.

Page 20of 61It is important to point out that affinity maturation had already taken place in the human host, and therefore 
no in vitro affinity maturation was required to increase the natural binding affinity of MABp1. Also 
important is the fact that, unlike most other therapeutic IgG products, for which the Fc regions are derived 
from a rare human allele, XBiotech’s product includes a heavy chain in which the constant (CH) region 
represents an allele found in approximately 70% of the human population. These two features should make 
for a drug product with reduced potential for immunogenicity.
2.2 DRUG PRODUCT (BERMEKIMAB 200 MG/ML) DESC RIPTION
XBiotech’s dosage form is a sterile liquid formulation of 200 mg/mL bermekimab in a stabilizing isotonic 
subcutaneous formulation buffer at pH 6.2-6.5 containing non-active ingredients of low concentrations of 
sodium phosphate, citric acid and trehalose. The drug product is packaged in pre-filled syringes. Drug 
product in syringes is stored at 2 -8°C and is recommended to be protected from light.
2.3 STORAGE
The recommended storage condition is at 2 -8°C.
2.4 STABILITY
The drug product is formulated in a buffer in which most of the tonicity comes from trehalose rather than 
salt. Trehalose is an effective stabilizer against oxidation, aggregation, and therma l ormechanical stress. 
Citrate was selected as the buffering age nt due to its antioxidant properties.
Extensive stability data indicates that the drug product is very stable, even under thermally and 
mechanically stressed conditions. Short excursions to room temperature have been shown to have no 
negative effect on th e product. However, the study treatment products are not to be frozen at any time.  The 
drug product is labeled with a 12-month retest date. Every lot is also subjected to ongoing stability analysis 
per ICH guidelines. 
2.5 DESIGNATED INDIVIDUA L FOR DRUG ADMINISTRATION
To ensure that no unintentional unblinding occurs during study drug administration, a qualified individual 
will be designated at each study site to perform all preparation and injection of the investigational 
product. The designated inject or should have no other contact with the participant during the study, should 
not discuss the participant’s treatment with the participant, participant’s caregiver, or other site personnel 
at any time, and will not be permitted to review the participant’s medical records, questionnaires, or the 
Page 21of 61electronic CRF prior to each injection. The designated injector should be documented in the source 
documents at each visit.
2.6 METHOD OF ADMINISTRATION
Each injection should be administered at least one inch from p revious injection sites.  
Instructions	For	Subcutaneous	Injection
*At least 45 minutes prior to injection, remove the pre- filled syringe from refrigeration.
Lay the syringe on a flat surface and let it naturally warm to room temperature before injection. 
It may also be warmed by holding in hand. Do not heat the syringe.
Materials
Bermekimab pre -filled syringe for injection, warmed to room temperature
Sterile a lcohol wipes
Band- aids, along with 2x2 gauze bandages and paper tape
Latex -free gloves
Injection Site
Abdomen, at least 2 inches away from the belly button (Figure 3)
(Note: avoid areas where the skin is burned, scarred, hardened, inflamed, swollen or damaged )
Figure 3
Injection
Put on gloves
Wipe injection site clean with alcohol pads

Page 22of 61Raise a fold of skin between the thumb and forefinger andinsert needle as illustrated (Figure 4). 
Inject drug as rapidly as is comfortable for the patients.
Withdraw needle. Place band -aid over injection site ifdesired (Note: If bleeding occurs, hold 
pressure on the injection site for 90 seconds or until bleeding stops, and then apply gauze 
bandage secured by tape ).
Figure 4
2.
7 AGENT ORDERING
The Responsible Investigational Pharmacy will order study drug from XBiotec h’s contract drug distributor 
as needed. 
2.8 POTENTIAL DRUG INTERACTIONS
There are no known drug interactions reported with bermekimab.
2.9 CONCOMITANT THERAPY
2.9.1 Antihistamine/NSAID Use
Concomitant medications such as antihistamines and/or NSAIDs (ibuprofen is recommended) are allowed 
based on the Investigator’s judgement, in order to prevent or treat injection site reactio n or discomfort . This 
information must be captured in eCRF.
2.
9.2 Required Treatment
All patients are required to apply moisturizers at least twice daily for at least 7 days before visit 1 (day 0) 
and to continue the treatment throughout the study (up to36 weeks where applicable). All types of 
moisturizers are permitted, but patients may not initiate treatment with prescription moisturizers or 
moisturizers containing additives during the screening period or during the study. Patients may continue 

Page 23of 61using stable doses (for at least 7 days prior to screening visit) of such moisturizers if initiated before the 
screening visit. All moisturizer use must be captured in eCRF.
2.9.3 P ermitted Medications andProcedures
Use of concomitant medications is permitted if not listed in section 2.9Prohibited Medications and 
Procedures. Permitted concomitant medications includes basic skin care (cleansing and bathing, including 
bleach baths), moisturizers (required as background treatment), topical anesthetics, antihistamines, and 
topical and system ic anti-infective medications for any duration. In addition, medications used to treat 
chronic disease such as diabetes, hypertension, and asthma are permitted. 
Any questions regarding treatment with concomitant medication during the study, should be dire cted to the 
medical monitor. 
2.10 PROHIBITED MEDICATIONS AND PROCEDURES
Treatment with the following concomitant medications is prohibited during the entire duration of the study :
Topical tacrolimus and pimecrolimus
Treatment with a live (attenuated) vaccine
Treatment with other investigational drugs (besides Bermekimab) 
Treatment with topical corticosteroids or topical calcineurin inhibitors; such agents may be 
administered during the study only if required for atopic dermatitis rescue.  If topical corticosteroids 
and/or topical calcineurin inhibitors are used during the study, study treatment may continue as 
planned.
Treatment with systemic corticosteroids or nonsteroidal systemic immunosuppressive drugs (e.g., 
cyclosporine, methotrexate, mycophenola te-mofetil, azathioprine, etc.), except if required for 
atopic dermatitis rescue, or if critically medically needed to treat concurrent medical conditions 
(e.g., asthma).
oTheuseofsystemic corticosteroids forindications other than ADshould belimited
tosituations forwhich, intheopinion ofthetreating physician, there areno
adequate alternatives. They should beused on a short -term basis, preferably for
≤2weeks. Longer -term useofcorticosteroids should bediscussed with the
medical monitor ordesignee and may require discontinuation ofstudy drug.
Inhaled, otic, ocular, nasal orother routes ofmucosal delivery ofcorticosteroids
areallowed throughout thestudy.
Leukotriene inhibitors
Page 24of 61Allergen immunotherapy
Systemic treatment for AD with an immunosuppressive/immunomodulating substance (including, 
but not limited to, cyclosporine, mycophenolate -mofetil, IFN-γ, azathioprine, methotrexate, or 
biologics)
Study drug will be discontinued if any of the following are used through week 16: 
Treatment with a live (attenuated) vaccine
Treatment with investigational drugs other than bermekimab .
Treatment with systemic corticosteroids or nonsteroidal systemic immunosuppressive drugs (e.g., 
cyclosporine, methotrexate, mycophenolate -mofetil, azathioprine, et c.)
The following concomitant procedures are prohibited during study participation:
Surgical procedures
Concomitant ultraviolet (UV) procedures (phototherapy [NBUVB, UVB, UVA1, or PUVA])
Tanning in a bed/booth
Patients are not allowed more than 2 bleach baths per week during study participation
2.11RESCUE TREATMENT
Rescue treatment for AD may be provided to patients if medically necessary (ie, to control intolerable AD 
symptoms) at the discretion of the investigator . Topical calcineurin inhibitors may beused for rescue 
treatment, but should only be used for problem areas (e.g. face, neck, intertrinous and genital areas, etc). If 
possible, investigators should attempt to limit the first line of rescue treatment to topical medications. 
However, if the patient does not respond adequately to topical medications after at least 7 days, systemic 
medications may be used. 
3. STUDY DESIGN AND OBJECTIVES
This is a phase II, randomized, double -blind, placebo -controlled study to further establish the efficacy and 
safety and explore dose effects for bermekimab monotherapy in adults with moderate to severe Atopic 
Dermatitis (AD). Patients will be assessed for study eligibility at the initial screening visit after providing 
informed consent. Thirty days are allowed in the screening window to complete all screening procedures 
and randomize the subject. During the screening period, certain treatments will be washed out, as 
Page 25of 61applicable, according to eligibility requirements. Patients who fail initially may be re-screened oncebased
ontheinvestigator discretion butonly ifinclusion criteria aremetattime ofre-screening.
The study is approximately 40 weeks (30 day screening period, 32- week treatment period and a 4-week 
follow -up period) for all subjects. 
Patients who meet the eligibility criteria at screening will be randomized in a 1:1:1 ratio to one of two 
treatment arms or placebo:
Arm 1: 800 mg of bermekimab + placebo loading dose (2mL SC injection containing 400 mg of 
bermekimab and one 2mL SC injecti on of placebo) at week 0 followed by weekly (qw) 
subcutaneous (SC) injections of 400 mg bermekimab through week 31
Arm 2: 800 mg loading dose of bermekimab (2 x 400 mg SC injections) at week 0 followed by 
subcutaneous (SC) injections of 400 mg bermekimab every other week (q2w) alternating with 
matching placebo q2w through week 31
Arm 3: 4mL loading dose of placebo (2 x 2mL SC injections) at week 0 followed by weekly 
placebo injections from weeks 2 through week 15. Patients in Arm 3 will begin to receive weekly 
(qw) blinded subcutaneous (SC) injections of 400 mg bermekimab beginning at week 16 through 
week 31.
In order to maintain blinding, all patients will receive two injections at week 0and 16, followed by weekly 
injections from week 1 to 31.Additionall y, at least one qualified individual will be designated at each 
study site to perform all preparation and injection of the investigational product. The designated 
injector(s) should have no other contact with the participant during the study, should not discuss the 
participant’s treatment with the participant, participant’s caregiver, or other site personnel at any time, and 
will not be permitted to review the participant’s medical records, questionnaires, or the electronic CRF 
prior to each injection. The designated injector(s) should be documented in the source documents at each 
visit.
During the 32-week treatment period, patients will attend weekly clinical study visits. Clinical 
assessments, collection of samples for bermekimab concentrations, and safety testing will be performed 
at specified clinic visits.  After completion of the 36 -week study period, data will be locked and analyzed 
for safety and efficacy endpoints for all arms. In addition to the analyses that will be performed following 
the formal database lock at the end of the study at Week 36, an additional database lock may beperformed 
Page 26of 61at Week 16, and interim analyses utilizing unblinded efficacy data available as the study progresses, may 
also be conducted to help plan potential future development activities. An internal interim analysis 
committee (IAC) will be established to review the interim data and formulate recommended 
decisions/actions. The IAC will consist of at least a clinician and a statistician (neither of whom are 
involved in study conduct or compound development), one of whom will chair the committee, and may 
also include other members as required by the nature of the IAs. Details will be provided in a separate 
IAC charter, which will define the organization and roles and responsibilities of the committee, possible 
recommendations or requests, and the communica tion process following IA reviews. Results from the 
Week 16 database lock and/or interim analyses will not be disseminated to investigators or subjects 
participating in the study.  In addition, results of the interim analyses will not be disseminated to 
individuals associated with the conduct of the study.
Patients will be monitored at a follow up visit (visit 34/week 36) for safety and clinical assessments after 
completing the 32 week treatment period. . 
The protocol of the study will be approved by theInstitutional Review Board (IRB) or the Ethics Committee 
(EC) of the participating study sites. Depending on the participating countries both local and central IRB/EC 
approvals will be granted. The study will be registered at www.clinicaltrials.gov before the enrollment of 
the first patient into the study .  The trial will be conducted in compliance with the protocol, GCP, and all 
applicable regulatory requirements.
3.1 Study Endpoints :
Primary Endpoint(s):
Percentage of Patients achieving Eczema Area and Severity Index -75 (EASI -75) (≥75% 
improvement from baseline) at week 16.
Secondary Endpoints:
Percentage of patients achieving ≥4-point improvement (reduction) in the weekly average peak 
daily Pruritus Numeric Rating Scale (NRS) score from baseline to weeks 4, 8, 12, 16, and 32 in 
patients with baseline score ≥4.*
Percentage of patients achieving ≥4-point im provement (reduction) in the weekly average overall 
Pruritus Numeric Rating (NRS) from baseline to weeks 4, 8, 12 16, and 32in patients with baseline
score ≥4.* 
Page 27of 61Percentage of patients achieving ≥4-point improvement (reduction) in the weekly average peak 
daily Pain Numeric Rating Scale (NRS) score from baseline to weeks 4, 8, 12, 16, and 32 in patients 
with baseline score ≥4.*
Percentage of patients achieving ≥4-point im provement (reduction) in the weekly average overall 
Pain Numeric Rating (NRS) from baseline to weeks 4, 8, 12, 16, and 32 in patients with baseline 
score ≥4.*
Percentage of patients achieving EASI -75 (≥75% improvement in Eczema Area and Severity Index 
Score [EASI] from baseline) at weeks 4, 8 , 12, and 32 .*
Percentage of patients achieving an Investigators Global Assessment (IGA) score of 0 or 1 (on a 5-
point scale) and a reduction in this measure from baseline of at least 2 points at week 16.
Percentage of patients achieving EASI -90 (≥90% improvement in Eczema Area and Severity Index 
Score [EASI] from baseline) at weeks 12 , 16, and 32 .*
Change in Dermatology Life Quality Index (DLQI) from baseline to weeks 8, 12, 16 , and 32. *
Change in Hospital Anxiety Depression Scale (HADS) (Anxiety) from baseline to weeks 8, 12, 16 , 
and 32.*
Change in Hospital Anxiety Depression Scale (HADS) (Depression) from baseline to weeks 8, 12 , 
16, and 32. *
Change in Patient Oriented Eczema Measure (POEM) Score s from baseline to weeks 8, 12, 16, and 
32.*
Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to weeks 8, 12, 16, and 
32.*
Change in Global Individual Signs Score (GISS) from baseline to weeks 8, 12 , 16, and 32.*
Exploratory Endpoints:
Percentage of patients achieving an IGA score 0 or 1 (on a 5-point scale) and a reduction in this 
measure from baseline of at least 2 points at week 12.
Change in Eczema Area and Severity Index Score (EASI) from baseline to weeks 8, 12, 16, and 
32.
Change from baseline to week 4 in Dermatology Life Quality Index (DLQI).
Patients (%) achieving 50% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, and 32.*
Patients (%) achieving 75% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, and 32.*
Patients (%) achieving 90% reduction in SCORAD Score at Weeks 4, 8, 12 , 16, and 32.*
Change from baseline to week 8, 12, 16, and 32 in percent Body Surface Area (BSA).*
Page 28of 61Safety Endpoints: 
Incidence of skin infection treatment -emergent adverse events (TEAEs) requiring systemic 
treatment from baseline through week 16 and 32.
Incidence of treatment -emergent serious adverse events (TESAEs) from baseline through week 16 
and 32.
Incidence of TEAEs leading to treatment discontinuation from baseline through week 16 and 32.
*Each listed time point (in weeks) will be measured separately and treated as an individual endpoint. 
Page 29of 614. ELIGIBILITY CRITERIA
4.1 I NCLUSION CRITERIA
No waivers/exemptions will be granted for protocol inclusion/exclusion criteria.
Subjects are included in the study if they meet all of the following criteria:
Written informed consent provided by the patient.
Male or female, at least 18 years.
Willing and able to attend all clinic visits and comply with study -related procedures
Is able to understand and complete study -related questionnaires
Chronic atopic dermatitis present for at least 3 years.
EASI score ≥16 at screening and baseline visits.
IGA score ≥3 at screening and baseline visits.
Baseline pruritis numerical rating scale average score for maximum intensity of at least 3, based 
on the average of daily pruritis numerical rating scale scores for maximum itch intensity reported 
during the 7 days prior to randomization.
Has applied a stable dose of topical moisturizer twice daily for at least 7 consecutive days 
immediately prior to the baseline visit andis willing to continue this regimen on a daily basis for 
the duration of the study.
≥10% body surface area (BSA) of AD involvement at screening and baseline vi sits.
Documented recent history (within 6 months prior to screening) of inadequate response to treatment 
with topical medications, or patients for whom topical treatments are medically inadvisable 
(because of important side effects or safety risks).
a)Inadequate response is defined as failure to achieve and maintain remission or a low 
disease activity state (comparable to an IGA score of 0-2), despite treatment with a daily  
regimen of topical corticosteroids of medium to higher potency (with or without topical 
calcineurin inhibitors as appropri ate), applied for at least 28 days or for the maximum 
duration recommended by the product prescribing information, whichever is shorter.
b)Patients with documented systemic treatment for atopic dermatitis in the preceding 6 
months are also considered to be inadequate responders to topical treatments and are 
potentially eligible for treatment with bermekimab, after appropriate washout.
c)Important side effects or risks are those that outweigh the potential treatment benefits, and 
include: intolerance to treatment, hypersensitivity reactions, significant skin atrophy, and 
adverse systemic effects.
Page 30of 61d)Acceptable documentation includes contemporaneous chart notes that record topical 
medication prescription and treatment outcome, or investigator documentation based on 
communication with the patient’s treating physician.
4.2 E XCLUSION CRITERIA
Subjects with ANY of the following will be excluded from the study:
Age below 18 years as the current study is evaluating bermekimab in adult patients only 
Subject has been treate d for AD with any investigational drug of chemical or biologic nature within 
a minimum of 30 days or 5 half -lives (whichever is longer) of the drug prior to baseline
Treatment with bermekimab at any time in the past.
Treatment with immunosuppressive/immuno modulatory drugs or phototherapy for atopic
dermatitis within 4 weeks of baseline, or any condition that, in the opinion of the investigator, is 
likely to require such treatment(s) during the first 4 weeks of study treatment
Treatment with topical corticosteroids or topical calcineurin inhibitors for the treatment of AD 
within 14 days prior to baseline]
Treatment with biologics as follows:
a)Any cell-depleting agents including, but not limited to, rituximab, within 5 half-lives (if 
known) or 30 days prior to baseline visit, or until lymphocyte count returns to normal, 
whichever is longer .
b)Other biologics: within 5 half -lives (if known) or 30 days prior to baseline visit, whichever 
is longer
Initiation of treatment of atopic dermatitis with prescription moisturizers or moisturizers
containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products 
during the screening period (patients may continue to use stable doses of such moisturizers if 
initiated before the screening visi t)
Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the screening 
visit
Planned or anticipated use of any prohibited medications and procedures during study treatment
Treatment with a live (attenuated) vaccine within 30 days prior to the screening visit
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, 
antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to the baseline visit, or superficial 
skin infections within 1 week prior to the baseline visit. NOTE: patients may be rescreened after 
infection resolves
Page 31of 61Known or suspected history of immunosuppression, including history of invasive opportunistic 
infections (e.g., tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, 
aspergillosis) despite infection resolution; or unusually frequent, recurrent, or prolonged infections, 
per investigator judgment.
History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening
Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody at the 
screening visit
At baseline, presence of any conditions listed as criteria for study drug discontinuation
Presence of skin comorbidities that may interfere with study assessments
History of malignancy within 5 years before the screening visit, except completely treated in situ 
carcinoma of the cervix, and completely treated and resolved non-metastatic squamous or basal 
cell carcinoma of the skin.
Severe concomita nt illness(es) that, in the investigator ’s judgment, would adversely affect the 
patient ’s participa tion in the study. Examples include, but are not limited to, patients with short life 
expectancy, patients with uncontrolled diabetes (HbA1c ≥ 9%),  patients with cardiovascular 
conditions (eg, stage III or IV cardiac failure according to the New York Heart Association 
classification), severe renal conditions (eg, patients on dialysis), hepato -biliary conditions (eg, 
Child -Pugh class B or C), neurological cond itions (eg, demyelinating diseases), active major 
autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other 
severe endocrinological, gastrointestinal, metabolic, pulmonary or lymphatic diseases. The specific 
justificati on for patients excluded under this criterion will be noted in study documents (chart notes, 
case report forms [CRFs], etc.)
Planned or anticipated major surgical procedure during the patient’s participation in this study
Patient or immediate family member is part of the current clinical investigational team
Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the 
study
Women unwilling to use adequate birth control, if of reproductive potential and sexually 
active. Adequate birth control is defined as consistent practice of an effective and accepted method 
of contraception throughout the duration of the study and for 120 days after the last dose of study  
drug. These methods include oral contraceptives (stable use for more than 3 months before 
Screening), intrauterine device (IUD), hormonal contraceptives such as Depo -Provera (stable use 
for m ore than 3 m onths before Screening), Implanon implants (stable use for more than 3 months 
before Screening), double barrier contra ception such as condom or diaphragm used with 
Page 32of 61contraceptive sponge, foam, or jelly. For men participating in the study, unwillingness of sexual 
partner to use any of the above contraception methods.
History of severe allergic or anaphylactic reactions to monoclonal antibodies.
Any other medical or psychological condition (including relevant laboratory abnormalities at 
screening) that, in the opinion the investigator, may suggest a new and/or insufficiently understood 
disease, may present an unreasonable risk to the study patient as a result of his/her participation in 
the study, may make patient’s participation unreliable, or may interfere with study assessments. 
The specific justification for patients excluded under this criterion will be noted in study documents 
(chart notes, case report forms, etc.)
5. TREATMENT PLAN
5.2 STUDY PROCEDURES 
PLACEBO -CONTROLLED PERIOD
Screening (maximum 30 days): The screening period begins once the informed consent is signed.  
Informed Consent 
Inclusion/ Exclusion
Demographics
Medical History 
Concomitant Medications/Treatments 
Physical Exam
Electrocariogram
Vital Signs (blood pressure, pulse, oxyen saturation, respiratory rate and body temperature) 
Height
Weight
Body Mass Index (BMI) [BMI= weight (kg)/height (m2)]
Patient Diary 
Patient Oriented Eczema Measure (POEM)
Hospital Anxiety and Depression Scale (HADS)
Dermatology Life Quality Index (DLQI)
Investigator’s Global Assessment (IGA)
Eczema Area and Severity Index (EASI)
Global Individual Signs Score (GISS)
SCORing Atopic Dermatitis (SCORAD)
Body Surface Area (BSA) involvement with atopic dermatitis (must be greater than 10%)
Urinalysis: pH, protein, glucose and blood cells (RBCs and WBCs)
Blood Draw:
Page 33of 61Chemistry panel: Albumin, Alkaline Phosphatase, ALT, AST, GGT, Bicarbonate (CO2), 
Calcium, Chloride, Creatinine, Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, 
Urea Nitrogen
Hematology Panel:  Complete Blood Count (CBC) with differential and p latelets
Infectious disease screening: HIV antibody, Hepatitis C antibody, Hepatitis B panel 
(HBsAg, anti -HBc, anti- HBs), and interferon gamma release assay (IGRA)
Serum pregnancy test for WOCBP
Inflammation Markers: CRP (C -Reactive Protein), ESR (Erythrocyte Sedimentation Rate)
Randomization to study arm (once confirmed patient has passed screening requirements).
***Patients	will	be	monitored	at	the	study	site	at	visits	1,	2,	3,	17,	18	&	19	(weeks	0,	1,	2,	16,	17	&	18)	
for	a	minimum	of	30 -minutes	after	st udy	drug	administration.	Vital	signs	and	AE	assessments	will	be	
done	at	30	minutes	(+/ -10	minutes)	post -injection.***
Visit 1 (Baseline/Week 0/Day 0) (must occur within 30 days of signing informed consent)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
Verify patient still meets all Inclusion/ Exclusion criteria
Height , Weight , BMI
Patient Diary
POEM , HADS , DLQI
EASI , GISS, SCORAD , BSA , IGA
Vital signs , Urine Pregnancy
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, PD (including 
IL-6), biomarker and research analysis
Bermekimab/placebo subcutaneous injection (To deliver a loading dose to subjects in the 
bermekimab groups while maintaining blinding, all subjects will receive two injections)
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 2 (Week 1/Day 7 ± 3 days) ; Visit 3 (Week 2/Day 14 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
Patient Diary
POEM , HADS , DLQI
IGA, EASI , GISS, SCORAD , BSA
Vital signs , Urine Pregnancy
Blood draw for PK/ADA, PD (including IL -6), biomarker and research analysis
Page 34of 61Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 4 (Week 3/Day 21± 3days) ; Visit 6 (Week 5/Day 35 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
Patient Diary
Vital signs , Urine Pregnancy
Blood draw for PK/ADA, PD (including IL -6), biomarker and research analysis
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 5 (Week 4/Day 28 ± 3 days) ; Visit 13 (Week 12/Day 85 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
Patient Diary
POEM, HADS , DLQI
EASI, GIS S, SCORAD , BSA , IGA
Vital signs , Urine Pregnancy
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, PD (including 
IL-6), biomarker and research analysis
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 7 (Week 6/Day 42 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
oPatient Diary
oPOEM, HADS , DLQI
oEASI, GISS , SCORAD , BSA , IGA
oVital signs, Urine Pregnancy 
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Page 35of 61Concomitant medications/treatments
Visit 8 (Week 7/Day 49 ± 3 days) ; Visit 10 (Week 9/Day 63 ± 3 days) ; Visit 11 (Week 10/Day 70 ± 3
days) ; Visit 12 (Week 11/Day 77 ± 3 days) ; Visit 14 (Week 13/Day 91 ± 3 days) ; Visit 15 (Week 
14/Day 98 ± 3 days) ; Visit 16 (Week 15/Day 105 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. The syringe may be held in the hand to warm. Do not heat. 
Pre-injection
Patient Diary
Vital signs , Urine Pregnancy
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 9 (Week 8/Day 56 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat.
Pre-injection
Patient Diary
POEM, HADS , DLQI
EASI, GISS , SCORAD , BSA , IGA
Vital signs, Urine Pregnancy 
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, PD (including 
IL-6), biomarker and research analysis
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
BLINDED ACTIVE DOSING PERIOD
Visit 17 (Week 16/Day 112 ± 3 days)
At least 45 minutes before injection: Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature. Syringe may be held in hand to warm. Do not heat
Pre-injection
Patient Diary
POEM, HADS , DLQI
EASI, GISS , SCORAD , BSA , IGA
Physical Examination , Vital signs , Urine Pregnancy
Urinalysis
Page 36of 61Blood draw for chemist ry, hematology, inflammation markers, PK/ADA, PD (including IL-6), 
biomarker and research analysis
Bermekimab/placebo subcutaneous injection 
Post-injection
Adverse event monitoring
Concomitant medications/treatment s
Visit 18 (Week 17 /Day 119 +/ -3); Visit 19 (Week 18 /Day 126 +/-3); Visit 20 (Week 19 /Day 133 +/ -3); 
Visit 22 (Week 21/Day 147 +/-3); Visit 23 (Week 22) (day 154 +/-3); Visit 24 (Week 23) (day 161 +/-
3); Visit 26 (Week 25/D ay 175 +/ -3); Visit 27 (Week 26 /Day 182 +/ -3); Visit 28 (Week 27 /Day 189 +/-
3); Visit 30 (Week 29/D ay 203 +/ -3); Visit 31 (Week 30 /Day 210 +/ -3); Visit 32 (Week 31 /Day 217 +/ -
3):
At least 45 minutes before injection :  Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature.  Do not heat
Pre-injection
Patient Diary
Vital Signs, Urine Pregnancy 
Bermekimab/placebo subcutaneous injection 
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 21 (Week 20 /Day 140 +/ -3); Visit 29 (Week 28 /Day 196 +/ -3):
At least 45 minutes before injection :  Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature.  Do not heat
Pre-injection
Patient Diary
POEM, HADS, DLQI
EASI, GISS, SCORAD, BSA, IGA
Vital Signs , Urine Pregnancy 
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 25 (Week 24/Day 168 ± 3 days)
At least 45 minutes before injection :  Remove syringe from refrigeration and lay flat; allow to 
warm to room temperature.  Do not heat
Pre-injection
Patient Diary
POEM, HADS , DLQI
EASI, GISS, SCORAD, BSA, IGA
Page 37of 61Vital Signs , Urine Pregnancy 
Urinalysis
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, biomarkers and 
research analysis 
Bermekimab/placebo subcutaneous injection
Post-injection
Adverse event monitoring
Concomitant medications/treatments
Visit 33 (Week 32 /Day 224 +/-3)
Patient Di ary
POEM , HADS , DLQI
IGA, EASI , GISS, SCORAD , BSA
Physical Exam , Vital Signs , Urine Pregnancy 
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, biomarkers and 
research analysis 
Adverse event monitoring
Concomitant medications/treatments
FOLLOW -UP PERIOD
POEM, HADS , DLQI
IGA, EASI, GISS, SCORAD, BSA
Physical Exam, Vital Signs , Urine Pregnancy 
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, PK/ADA, biomarkers and 
research analysis 
Adverse Events
Concomitant medications/treatments
UNSCHEDULED VISIT (if applicable)
Patient Diary
POEM, HADS , DLQI
IGA, EASI, GISS, SCORAD, BSA
Physical Exam, Vital Signs, Electrocardiogram, Urine / Serum Pregnancy 
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, infectious disease panel, 
PK/ADA, biomarkers and research analysis 
Adverse Events
Concomitant medications/treatments
Page 38of 61EARLY TERMINATION VISIT (if applicable)
Patient Diary
POEM, HADS , DLQI
IGA, EASI, GISS, SCORAD, BSA
Physical Exam, Vital Signs 
Urinalysis 
Blood draw for chemistry, hematology, inflammation markers, infectious disease panel, 
PK/ADA, biomarkers and research analysis , Serum Pregnancy
Adverse Events
Concomitant medications/treatments
Page 42of 615.3 DISCONTINUATION OF THERAPY
If a patient is discontinued from study, the reason for discontinuation/withdrawl must be clearly 
documented in the source documentation and the EDC. Every effort should be made by the investigative 
site to have subjects who discontinue early from study complete all assessments included in the Early 
Termination visit included in the study calendar provided in section 5. All subjects will be unblinded after 
clinical database lock .
Study therapy MUST immediately be discontinued for any the following reasons: 
Withdrawal of informed consent (subject’s decision to withdraw for any reason) 
Any clinical adverse event, laboratory abnormality, inter -current illness, or clinical progression of 
disease which, in the opinion of the Principal Investigator, indicates that continued participation 
in the study is not in the best interest of the subjec t 
Pregnancy 
Termination of the study by the sponsor
Imprisonment or the compulsory detention for medical treatment.
5.4 TRIAL STOPPING RULES
Sponsor may terminate this study prematurely, either in its entirety or at any study site, for reasonable cause 
provided that written notice is submitted in advance of the intended termination. The investigator may also 
terminate the study at his/her site for reasonable cause, after providing written notice to Sponsor in advance 
of the intended termination. Advance notice is not required by either party if the study is stopped due to 
safety concerns. If Sponsor terminates the study for safety reasons, Sponsor will immediately notify the 
investigator by phone and subsequently provide written instructions for study ter mination.
5.5 EMERGENCY UNBLINDING
Subjects and investigators will be unblinded to their treatment allocation after database lock. In the event 
of an emergency that would require the investigator to be aware of the treatment allocation prior to the end 
of thetrial, the investigator can obtain this information, on a per subject basis, after consultation with the 
Sponsor’s Medical Monitor, if possible. Every effort should be made to consult with the Medical Monitor 
prior to emergency unblinding. Events that qua lify as emergencies are as follows:
Page 43of 61A grade 3 or greater AE which are “probably or definitely” related to study drug, and only if 
treatment assignment information is essential for the management of the event . This type of 
reaction would require that the patient receives no further doses, and is followed until the resolution 
of the toxicity.
Any suspected, unexpected, serious adverse reaction (SUSAR)
Pregnancy
6. CORRELATIVE STUDIES
6.1 PHARMACOKINETICS (PK) SAMPLE COLLECTION
The process for the collection, storage, future use and disposal of biological samples will follow company 
policies and SOPs. Patient blood will be drawn into blood collection tubes at each collection time point per 
the study protocol forPK/ADA/PD/researc h analysis. These samples will be processed by the collection 
lab per the study laboratory manual and the obtained plasma/serum will besent to a central laboratory 
before being shipped to XBiotech in monthly batches for analysis.
An enzyme -linked immunos orbent assay (ELISA) has been developed and validated to specifically 
measure bermekimab levels in human plasma. Blood samples will also be used to test for the presence of 
treatment -emergent antibodies against bermekimab. XBiotech has developed and valida tedan ELISA 
method to measure treatment -emergent ADA. Additionally, samples will be used for pharmacodynamic 
analysis and exploratory research.
7. ASSESSMENT OF SAFETY
Safety will be assessed by monitoring adverse events, vital signs, physical examinations, ECG, and clinical 
laboratory measurements. Data from ECG will be included in safety analysis only when all of these 
measures are available for each subject (baseline and last visit). Adverse events will be monitored from 
visit 1 (post -injecti on) through visit 34(week 36).Any serious adverse events whether related to study drug 
or not will be followed up until resolution.
Study drug, bermekimab, will be administered under close observation in a facility equipped to handle 
anaphylaxis or injec tion site reactions. Subjects must be closely monitored at the study site at visits 1, 2 and 
3 (for the first three injections) until at least 30 minutes following the administration of the antibody. Vital 
signs and AE assessments will be done at 30 minute s (+/- 10 minutes) post -injection.    
Page 44of 61Any grade 3 or greater injection site reaction must be reported to the sponsor within 24 hours of learning 
of the event.
8. STUDY VARIABLES
8.1 D EMOGRAPHIC AND DISEASE CHARACTERISTICS
Demographic characteristics will include standard demography (age, sex, race, weight, and BMI) medical 
history, medication history, and prior biologic use for each patient. Characteristics of the patient’ satopic 
dermatitis, including duration of disease, baseline EASI score (including individual signs score), baseline 
Investigator’s Global Assessment, baseline body surface area involvement, baseline pruritus numerical 
rating score, baseline SCORAD score, baseline patient -oriented eczema measure, baseline DLQI, and 
baseline HADS score, will be collected. Baseline is defined as the week 0(visit 1), pre-injection assessment.
8.2 STUDY ASSESSMENTS
Eczema Area and Severity Index
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent 
of AD. Four AD disease characteristics will be assessed for severity by the investigator or designee on a 
scale of “0” (absent) through “3” (severe). In addition, the area of AD involvement will be assessed as a 
percentage by body area of head, trunk, arms, and legs and converted to a score of 0 to 6.
Investigator’s Global Assessment
The IGA is an assessment scale used in clinical studies to determine severity of AD and clinical response 
to treatment based on a 5 -point scale ranging from 0 (clear) to 4 (severe).  
Global Individual Signs Score
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and
lichenification) will be rated globally (ie, each assessed for the whole body, not by anatom icalregion) on a 
4-point scale (from 0=none to 3=severe) using the EASI severity grading criteria.
SCORing Atopic Dermatitis
The SCORAD is a validated tool used in clinical research and clinical practice that was developed to 
standardize the evaluation of the extent and severity of AD.  There are 3 components to the assessment: A 
= extent or affected body surface area, B = severity, and C = subjective symptoms. The extent of AD is 
assessed as a percentage of each defined body area, and reported as the sum of all areas, with a maximum 
score of 100% (assigned as “A” in the overall SCORAD calculation). The severity of 6 specific symptoms 
of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/ lichenification, dryness) is assessed 
Page 45of 61using the fol lowing scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points, 
assigned as “B” in the overall SCORAD calculation). Subjective assessment of itch and sleeplessness is 
recorded for each symptom by the patient or relative on a VAS, where 0 is no itch (or sleeplessness) and 
10 is the worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is 
assigned as “C” in the overall SCORAD calculation. The SCORAD is calculated as: A/5 + 7B/2 + C where
the maximum is 103.  
Body surface area affected by AD will be assessed for each section of the body (the possible highest score 
for each region is: head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs 
[36%], and genitals [ 1%]) and will be reported as a percentage of all major body sections combined. Body 
Surface Area (BSA) will be extracted using SCORAD.
Numerical Rating Scale (NRS) for Pruritus & Pain
Patients will be given a diary to complete each night before bed. Patients will be asked to report “average 
pain”, and “worst moment pain” as well as “average itch” and “worst moment itch” on a 0-10 numeric 
rating scale. Patient diaries will be collected w eekly. 
Patient Oriented Eczema Measure
The POEM is a 7- item, validated questionnaire used in clinical practice and clinical trials to assess disease 
symptoms in children and adults. The format is a response to 7 item s (dryness, itching, flaking, cracking,
sleep loss, bleeding, and weeping) based on frequency during the past week (ie, 0 = no days, 1 = 1 to 2 
days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days) with a scoring system of 0 to 28; the total score 
reflects disease -related morbidity.  The PO EM is provided in the study reference manual.
Hospital Anxiety and Depression Scale
The HADS is an instrument for screening anxiety and depression in non -psychiatric populations; repeated 
administration also provides information about changes to a patient’s emotional state. The HADS consists 
of 14 items, 7 each for anxiety and depression symptoms; possible scores range from 0 to 21 for each 
subscale. The following cut-off scores are recommended for both subscales: 7 to 8 for possible presence, 
10 to11 for probable presence, and 14 to 15 for severe anxiety or depression.  The HADS is provided in 
the study reference manual.
Dermatology Life Quality Index
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the 
impact of AD disease symptoms and treatment on QOL. The format is a simple response (0 to 3 where 0 is 
“not at all” and 3 is “very much”) to 10 questions, which assess QOL over the past week, with an overall 
scoring system of 0 to 30; a high score is indicative of a poor QOL.  The DLQI is provided in the study  
reference manual.
Page 46of 61Pharmacokinetics (PK) and Interleukin -6 (IL -6)
An enzyme -linked immunosorbent assay (ELISA) has been developed to specifically measure bermekimab 
levels in human plasma. Blood will be drawn into three 6 ml collection tubes at each research draw 
collection time point as outlined in section 5 . These samp les will be collected per the study lab manual and 
shipped to the Sponsor for PK and IL-6 analyses. The samples will also be used for various 
pharmacodynamic (PD), biomarker, and general research analyses. The PK samples will also be used to 
test for the p resence of antibodies against bermekimab. The IL -6 samples will be used to test for change in 
serum IL-6 levels in patients, which has shown to correlate with disease severity in HS and potentially a 
more reliable predictor of treatment response in HS pati ents than CRPxvii, xviii. 
9. ADVERSE EVENTS 
9.1 DEFINITION OF ADVERSE EVENT (AE)
An adverse event is defined as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. An AE can therefore be any of the following:
Any unfavorable and unintended sign (including laboratory findings), symptom, or disease temporally 
associated with the use of bermekimab , whether or not it is apparently related to bermekimab
A concurrent illness
An exacerbation, or an unexpected increase in frequency or intensity of a preexisting condition, 
including intermittent or episodic conditions.  However, anticipated day-to-day fluctuations or 
expected progression of the preexisting condition (based upon the Investigator’s clinical judgment) 
are not to be considered AEs
A significant or unexpected worsening of the condition/indication under investigation.  However, 
anticipated day-to-day fluctuations or expected progression of the disease under investigation (based 
upon the In vestigator’s clinical judgment) are not to be considered AEs
A suspected interaction between the investigational drug and concomitant medications
Any clinically significant laboratory abnormality (including radiological interpretations, 
histopathological f indings, etc .)
9.2 DEFINITION OF SERIOUS ADVERSE EVENT (SAE)
An adverse event is considered “serious” if, in the view of either the investigator or sponsor, it results in 
any of the following outcomes: 
Death;
Page 47of 61A life -threatening adverse event;
Inpatient hospitalization or prolongation of existing hospitalization;
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions;
Congenital anomaly/ birth defect;
An important medical event that may not result in death, be life -threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of dru g dependency or drug abuse.
Note that seriousness and severity should not be confused. A subject could experience a severe headache 
that would not qualify as an SAE, while another might experience a mild stroke that, while not severe, 
would be considered serious.
9.3 RECORDING OF ADVERSE EVENTS
All untoward events occurring between visit 1 (week 0) (post-injection) and the end of study (or if subject 
terminates from study prior to visit 34 (week 36), five weeks after the last administration of bermekimab)
should be recorded on the eCRF, regardless of whether they are considered related to study drug.
All AEs should be recorded in standard medical terminology as concisely as possible.  The AE recorded 
should not be a procedure or a clinical/laboratory measurement but should reflect the event leading to the 
procedure or the cause of the clinical/laboratory abnormality, if known.  Whenever possible, AEs should 
be evaluated and recorded as a diagnosis, rather than individual signs and symptoms.  However , if a 
definitive diagnosis is not possible, the individual signs and symptoms should be recorded.  Any AE that 
worsens in intensity, or becomes serious, should be recorded as a new event.
9.4 EVALUATING ADVERSE EVENTS
All AEs will be graded according to the CTCAE version 5.
Page 48of 619.5 ASSESSMENT OF CAUSALITY
Investigators are required to assess the relationship, if any, of each AE or SAE to the investigational drug  
using clinical judgment to determine the degree of certainty with which an AE can be attributed to the 
investigational drug.  Alternative causes, such as natural history of the underlying disease, other risk factors,  
and the temporal relationship of the event to the administration of the study medication must be considered.
Relationship to study drug is summarized as follows:
Not Related:   There is another obvious cause of the AE
Unlikely to be related:   There is another more likely cause of the AE
Possibly related:  The AE could have been due to the investigational drug
Probably related:   The AE is probably attributable to the investigational drug
Definitely related:   The AE is most likely attributable to the investigational drug
9.6 REPORTING REQUIREMENTS 
Any grade 3 or greater injection site reaction must be reported to the sponsor within 24 hours of learning 
of the event.
All serious adverse events (SAEs) should be reported to the Sponsor on the initial SAE report forms within 
24 hours of knowledge of the event.  These immediate reports should be followed promptly by detailed, 
written reports (follow -up SAE reports). The subject should be followed up with until stabilization of the 
reported SAE, either with full satisfactory resolution or resolution with sequelae, or until death of the 
subject. Before declaring the subject is lost to follow -up, three unsuccessful attempts at contact should be 
made and recorded on the SAE form. The immediate and follow -up reports should identify subjects by 
unique code numbers (generated by the safety database) assigned to the trial subjects rather than by the 
subjects' names, personal identification numbers, and/or addresses. The Investigator should also submit 
SAEs to the IRB/EC according to their IRB/EC guidelines [ICH -GCP E6].  Drug-related Serious Adverse 
Events will be reported to the FDA by XBiotech’s Medical Safety Officer according to 21 CFR 312.32.
9.7 REFERENCE SAFETY INFORMATION: POTENTIAL ADVERSE REACTIONS
911 patients have been treated using bermekimab (either by infusions or subcutaneous injections) in patients 
with advanced solid tumors, advanced hematologic malignancies, metastatic colorectal cancer, peripheral 
vascular disease, type II diabetes, acne vulgaris, plaque psoriasis, pyoderma gangrenosum, atopic dermatitis 
and hidradenitis suppurativa.  Over 5000 doses of bermekimab were admin istered intravenously at 7.5 
Page 49of 61mg/kg and over 900 doses of bermekimab were administered subcutaneously with 50 mg/mL, 100 mg/mL 
and 200 mg/ mL formulations.
Bermekimab is a recombinant human IgG1 monoclonal antibody specific for human interleukin -1(IL-
1).  As such, it is an immunomodulator that has anti-inflammatory and anti -neoplastic properties.  Other 
agents that could be considered in the same pharmacologic class include biologic agents that target IL-1 
receptor antagonist and IL-1 beta. Potential risks for agents in this class include infusion or injection site 
reactions and risk of infection.
Bermekimab is considered to be a True Human monoclonal antibody. Unlike previous generations of 
humanized or fully human antibodies, the entire be rmekimab heavy and light chain sequences are identical 
to those found in naturally -occurring human IgG1, with the light and heavy chain variable regions being  
identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy  
individual.  No in vitro affinity maturation or modifications have been made to improve its natural binding 
affinity (211 +/- 31 pM).  We believe that a true hum an antib ody should be effectively non -immunogenic 
in humans and thus exhibit optima l activity and pharmacokineti cs.  To date, no treatment emergent anti-
drug antibodies specific to bermekimab have been identified.
The mechanism behind infusion or injection site reactions is not well understood. In some cases, it may 
involve a reaction against the antibody products themselves, particularly where the primary sequence of the 
antibody has been modified in vitro or is derived from non -human system or, against some minor residual 
component from the manufacturing process (i.e. host cell proteins). Bermekimab is derived from and has 
undergone immunological selection in humans, thus anti-bermekimab responses are highly unlikely. To 
date, there has been a very low incidence of injection site or infusion reactions observed (27 patients out of 
911 total; 3.0%).  In order to mitigate this class -specific risk, close monitoring is required during the 
bermekimab infusion/ injection and for at least 30 minutes after the end of the infusion/ injection for the 
first 3 doses.  Availability of resuscitation equipment must be ensured although this has never been used 
for any patient in any of our studies.  Pre -medication with antihistamines, NSAIDs or corticosteroids is not 
required but allowed at PI’s discretion.
An expanded discussion of potential risks and monitoring with bermekimab therapy is located in Section 
4.6 of the Investigator’s Brochure.
Page 50of 61For the purposes of expedited safety reporting in clinical trials, the following should be considered 
expected events:
Infusion Related Reactions
Injection Site Reactions
10.STATISTICAL PLAN
A general description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the statistical analysis plan (SAP ).
10.1 DETERMINATION OF SAMPLE SIZE
The primary efficacy endpoint is percentage of patients with Eczema Area and Seveirty Index -75 (EASI -
75) (≥75% improvement from baseline) at week 16 . The sample size is calculated for the bermekimab 
weekly injection group (arm 1) versus placebo group (arm 3) compari son (the primary comparison).
Assuming EASI -75 is achieved in 60% of intent -to treat (ITT)patients treated in the bermekimab weekly 
injection group (arm1) versus 20% in placebo treated patients (arm 3), then, for a randomization ratio of 
1:1:1, a sample size of 69 patients (23 in each treatment group) is required for approximately 80% power 
at a 0.05 significance level using a 2-sided Pearson chi-square test.  In order to account for possible dropouts 
and to provide adequate safety data, approximately 90 patients will be randomized and treated .
10.2 RANDOMIZATION
A centralized block randomization schedule with a 1:1:1 allocation ratio will be utilized using an electronic 
randomization system. Patients will be randomly assigned to either the bermekimab weekly injection group 
(arm 1), the bermekimab every other week injection group (arm 2), or the placebo group (arm 3).  The 
randomization schedule will be stratified by baseline EASI severity (less severe (EASI ≥16 and <28) or 
more severe (EASI ≥28)).
10.3 ANALYSIS SETS
The safety analysis set (SAF) population will consist of all patients who receive at least one dose 
of study medication and will be analyzed as treated.
The modified intent -to-treat ( mITT) population will consist of all randomized and treat ed patients.
Page 51of 6110.4 PATIENT DISPOSITION
A listing of all patients prematurely discontinued from the study, along with reasons for
discontinuation will be provided. In addition, the total number of patients for each of the
following categories will be summar ized.
The total number of screened patients: met the inclusion criteria regarding the target indication and 
signed the informed consent
The total number of patients in each analysis set (SAF, and m ITT)
The total number of patients who complete the study
The total number of patients who discontinued the study, and the reasons for discontinuation
10.5 STATISTICAL METHODS
Continuous data will be summarized for each treatment group using the number of observations available 
(N), means, standard deviation (SD), minimums, medians, and maximums.  Categorical data will be 
summarized for each treatment group using counts and percentages.  All statistical tests will be two -sided 
unless otherwise noted. 
10.5.1 Demography and Baseline Characteristics
Demographic and baseline characteristics will be summarized descriptively by treatment group.  
Continuous variables will be summarized with mean, median, SD, minimum, and m aximum.  Categorical 
variables will be summarized with frequency and percentage.
10.5.2 Safety An alysis
The primary objective of the study is to analyze the safety and efficacy of different dose regimens of 
bermekimab compared to placebo treatment in adult patients with moderate -to-severe AD
Safety endpoints will be evaluated by monitoring adverse events from clinical and laboratory reporting. 
The safety analysis will be based on the SAF population . A summary of safety results will be presented for 
each treatment group.
10.5.2.1 Analysis of Adverse Events
Adverse events reported in this study will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) coding dictionary (version 2 2.0 or newer). Coding will be to lowest level terms. The verbatim 
text, the PT, and the primary SOC will be listed in patient listings. 
Page 52of 61Pre-treatment AEs are defined as those that develop or worsen in severity from the time the patient provides 
informed consent, prior to the first dose of study drug.  Treatment emergent AEs (TEAEs) are defined as 
AEs that develop or worsen in severity following the first dose of study drug through the last study visit.
TEAEs will be grouped by MedDRA System Organ Class (SOC) and Preferred Term (PT) within SOC and 
will be presented for each treatment group. The number and percentage of patients experiencing AEs and 
TEAEs wil l be summarized by seriousness (SAEs), severity (grades 1 -5), and relationship.
10.5.2.2 Other Safety
Vital Signs
Summaries of vital sign parameters by treatment dose cohort will include:
Each vital sign parameter and change from baseline
Laboratory Tests
Clinical laboratory values will be converted to standard international units. Clinical laboratory (as described 
in the treatment plan) data will be listed for each subject. Laboratory data will be summarized by treatment 
group. Summaries of laboratory var iables by treatment group will include:
Each laboratory  result and change from baseline
Listing will be provided for patients with grade 2 or greater laboratory AEs
Electrocardiogram
12-lead ECG status (ie, normal, abnormal, clinically significant) will be summarized descriptively by 
treatment group.
10.5.3 Efficacy Analysis
In general, efficacy  analyses will include all randomized participants (mITT population) and will be 
analyzed based on the randomized treatment groups, regardless of the treatment t hey actually received.
10.5.3.1 Primary Efficacy Analysis
For the primary efficacy endpoint, the two bermekimab treatment groups will be com pared with placebo.  
To account for these two comparisons, testing will be done in a sequential manner, each at the 0.05 alpha 
level.  The bermekimab weekly injection group (Group 1) will be compared to the placebo group (Group 
3) first.  If this test is significant at the 0.05 level, then the bermekimab every other week injection group 
(Group 2) will be compared to the placebo group (Group 3).  Otherwise, the P- value for Group 2 vs Group 
Page 53of 613 will be considered nominal. This method to control the type-1 error will only be implemented for the 
primary efficacy analysis variable.
The number and percentage of patients with Eczema Area and Seveirty Index -75 (EASI -75) (≥75% 
improvement from baseline) at week 16will be presented by treatment group.  Patients who terminate from 
the study early prior to week 16 will count as non-responders (non-achievers) in the primary efficacy  
analysis (Non- Responder Imputation).  If a patient received rescue medication, the patient will be counted 
as a non-responder from the start of rescue medication.  Additional treatment failure rules and sensitivity 
analyses will be discussed in the statistic al analysis plan.  
A Cochran-Mantel- Haenszel (CMH) general association test stratified by baseline EASI severity will be 
used to compare each bermekimab dose separately with placebo.  The primary efficacy analysis population 
will be the mITT population.  
10.5.3.2 Secondary Efficacy Analyses
Secondary and exploratory efficacy endpoints will be summarized using descriptive statistics for 
continuous variables (n, mean, standard deviation, median, minimum and maximum value) and number 
and percentage for categorical variables.. The 95% CI of the m ean change from baseline will be provided. 
The change from baseline in these endpoints at each week will be analyzed using a restricted maximum 
likelihood (REML) -based mixed model for repeated measures (MMRM) with fixed effects for treatment, 
week, stratif ication factor ( baseline EASI severity ), baseline score, baseline score by week interaction, 
and the treatment -by-week interaction , if applicable .  The impact of the stratification factor will also be 
assessed.  Categorical variables will be analyzed using CMH tests as used for the primary efficacy 
analysis.  Full details will be provided in the SAP.
10.5.4 Treatment Exposure
The number and percentage of patients exposed to study drug along with duration of exposure will be 
summarized descriptively by trea tment group.
10.5. 5Pharmacokinetic (PK) and Pharmacodynamics (PD) Analysis:
Descriptive statistics of PK and PD concentrations and parameters will be presented.
Page 54of 6111. STUDY MANAGEMENT AND ADMINISTRATION
11.1 ETHICAL CONDUCT OF STUDY (GCP)
The guidelines of the World Medical Association Declaration of Helsinki in its revised edition (48th General 
Assembly, Somerset West, Republic of South Africa, October 1996), the guidelines of ICH GCP 
(CPMP/ICH/135/95), as well as the demands of national drug and data protection laws and other applicable 
regulatory requirements, will be strictly followed.  Approval will be obtained from the appropriate 
regulatory authorities before sites are initiated. 
11.2 IRB AND ETHICS COMMITTEE APPROVAL 
Prior to initiation of the study, the protocol, the informed consent form, the subject information sheet(s), 
details of the subject recruitment procedures and any other relevant study documentation will be submitted 
to the responsible IRB or Ethics Committee (EC). The Investigator will report promptly to the IRB/EC any 
new information that may adversely affect the safety of subjects or the conduct of the study. Similarly, the 
Investigator will submit written summaries of the study status to the IRB/EC annually, or more frequently 
if requested by the IRB/EC.  Upon completion of the study, the Investigator will provide the IRB/EC with 
a brief report of the outcome of the study, if required.
11.3 PROTOCOL MODIFICATIONS 
Modifications of the signed protocol are only possible by approved protocol amendments and with the 
agreement of all responsible persons.  The procedure for approval of a protocol amendment is identical to 
that for approval of the protocol.  The IRB/EC must be informed of all protocol amendments and sho uld be 
asked for its opinion as to whether a full re-evaluation of the ethical aspects of the study is necessary by the 
committee.  This should be fully documented.  The Investigator must not implement any deviation from or 
change to the protocol, without discussion with an dagreement by the study Sponsor .There also must first 
be prior review and documented approval/favorable opinion of the amendment from the relevant IRB/EC, 
except where it is necessary to eliminate an immediate hazard to study subjects, or where the change(s) 
involves only logistical or administrative aspects of the study (e.g., change in CRA(s), change of telephone 
number(s)). Protocol amendments will be submitted to the appropriate authority (s) as required by the 
applicable regulatory requirement(s).
Page 55of 6111.4 SUBJECT INFORMATION AND CONSENT 
The Investigator is responsible for ensuring that no subject will receive any study -related examination or 
activity before that subject has given an IRB/EC approved informed consent.  The subject must give written 
consent after the receipt of detailed information.  The verbal explanation will cover all the elements 
specified in the written information provided for the subject.  The Investigator will inform the subject of 
the aims, methods, anticipated b enefits and potential hazards of the study, including any discomfort it may 
entail.  The subject must be given every opportunity to clarify any points he/she does not understand and ,
if necessary, to ask for more information.  At the end of the interview, the subject may be given time to 
reflect if this is required, or if the subject requests more time.  Subject and/or legal guardian forms will be 
kept and archived by the Investigator in the Investigator's study file.  It should be emphasized that the 
subje ct is at liberty to withdraw their consent to participate at any time, without penalty or loss of benefits 
to which the subject is otherwise entitled.  Subjects who refuse to give, or withdraw, written informed 
consent may not be included or continued in t his study, but this will not impact their subsequent care.  The 
Investigator will notify in writing each subject’s primary care physician (or equivalent) of the subject’s 
intent to participate in the study.
11.5 DATA PROTECTION AND CONFIDENTIALITY 
By signing the final protocol, every participating Investigator agrees to keep all information and results 
concerning the study and the investigational product confidential.  The confidentiality obligation applies to 
all personnel involved at the investigational site.  The Investigator must ensure that each participant’s 
anonymity will be maintained in accordance with applicable laws. On eCRFs or other documents submitted 
to the Sponsor, subjects should not be identified by their name, but by subject ID number.  The Investigator 
should keep a separate log of ID numbers, names and addresses.  Documents that contain the names 
associated with these ID numbers (e.g., written consent/assent forms), are not for submission to the Sponsor 
and should be maintained by the Investigator in strict confidence except to the extent necessary to allow 
auditing by regulatory authorities, and auditing or monitoring by theInstitutional Review Board/EC, the 
Sponsor personnel or their affiliates and designees (such as CRAs). 
Copies ofradiological scans and autopsy reports (and other documents) that may be requested by the 
Sponsor should be de-identified.  The Investigator shall obtain all such permissions and authorizations as 
may be necessary or desirable to allow the collection and use of information protected under federal privacy 
laws and state privacy laws, including permission/authorization for monitoring and analysis (including re -
Page 56of 61analysis in combination with results of other studies), for regulatory submission purposes and for applicable 
reporting (if any) required to be made by Sponsor, its affiliates and their designee. 
Access to the study data will be strictly controlled. These data will be processed and archived in accordance 
with the applicable policies and SOPs. The Sponsor’s Electronic Database has security features which 
include but are not limited to the following: all application ports are secured behind a firewall; all data and 
network traffic is encrypted; the database is role-based and roles are customized to a llow restricted access 
to specific features; a password policy is enforced including a secure password length and complexity; all 
database changes and user logins are logged to an audit trail; fields containing Protected Health Information 
are obfuscated from study users (sponsor, data managers, etc.); and EU data are contained on a dedicated 
data server in the EU, so the data is not stored offshore.
11.6 STUDY REPORT AND PUBLICATIONS 
A final integrated clinical/statistical report will be prepared that is compliant with the ICH Harmonized 
Tripartite Guideline: Structure and Content of Clinical Study Reports (CPMP/ICH/137/95).  The results of 
this study will be published and/or presented at scientific meetings in a timely manner.  The publication 
policy is described in the contract between the Sponsor and Investigator. 
11.7 STUDY FILES AND RETENTION OF RECORDS 
Copies of all study documents should be retained by the Investigator until at least two years after the last 
approval of a marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least two years have elapsed since the formal discontinuation 
of clinical development of the investigational product, in accordance with 21 CFR 312.62.  These 
documents should be retained for a longer period however, if required by regulatory requirements or by 
agreement with the Sponsor.  It is the responsibility of the Sponsor to inform the Investigator/institution as 
to when these documents no longer need to be retained. The final database will be archived according to 
the regulatory requirements. 
11.8 CASE REPORT FORMS
Data for this protocol will be collected on to the source documents and later will be captured electronically 
in an Electronic Data Capture (EDC) system by the site coordinators.  Source documents are original 
Page 57of 61records of clinical findings, observations, or other activities in a clinical trial necessary for the evaluation 
of the trial. Examples of source documents (electronic or hardcopy documents) include but are not limited 
to subject diaries, physician and/or patient completed questionnaires or scales, laboratory results, ECGs and 
reports. Designated study pers onnel will be provided unique usernames and passwords with specific access 
within the electronic data collection system based on their role. The EDC system contains an audit trail 
associated with each individual's unique password that will document date and time of data entry and 
revisions.  All protocol -specified data is to be entered into the EDC system in a timely manner for review 
and audit by XBiotech. All data is to be entered such that it will allow accurate interpretation and tabulation.  
It is the Investigator's responsibility to ensure that all discontinued orders or changes in study or other 
medications entered into the database correspond to entries in the subject's medical records (i.e. source 
documents) and to acknowledge accurate completion of the eCRF.
11.9 DRUG ACCOUNTABILITY 
A Drug Dispensing Log must be kept current and should contain the following information: 
Initial inventory upon receipt of supplies at the study site 
Identification number of each subject to whom test drug was admini stered 
Date(s), quantities, lot numbers and calculations for all test drugs administered 
Final inventory (upon completion of the study)
This inventory must be available for inspection by the Clinical Research Associate.  The Investigator (or 
pharmacist, as appropriate) must maintain records of the delivery of the study medication to the study site, 
the inventory at the site, the usage for each subject, and destruction. The inventory must be available for 
monitoring, auditing or inspection.  A d rug dispens ing log must be kept current and should contain the 
following information: 
The subject identification number to whom the drug is dispensed 
The lot number of the drug dispensed 
The date(s) and the quantity of the drug dispensed to the subject
The sites will follow their internal SOPs for discarding the used (empty) syringes after the injection. The 
designated personnel at the sites will review drug accountability logs to account for administered syringes. 
Unused inventory by investigative sites at study completion should be returned to drug distributor for 
destruction per guidance provided in the study’s pharmacy manual.
Page 58of 6111.10 AUDITS AND INSPECTIONS 
Investigator sites, the study database and study documentation may be subject to quality assurance audits
during the course of the study either by the Sponsor or their appointed representatives.  In addition, 
regulatory bodies at their discretion may conduct inspections.  The Investigator shall permit the authorized 
Sponsor, agents of the Sponsor, and regulat ory agency employees to enter and inspect any site where the 
drug or records pertaining to the drug are held, and to inspect all records relating to an investigation, 
including subject records.  The Sponsor will not, however, copy any source data from the patient’s dossier.  
Completed eCRFs must be made available by the Investigator for review by the Sponsor, agents of the 
Sponsor, the CRA and the regulatory agencies.  To ensure the accuracy of data submitted, it is mandatory 
that representatives of the Sponsor and of the regulatory agencies have direct access to source documents 
(e.g., subject medical records, charts, laboratory reports, etc.).  Subject confidentiality will be protected at 
all times. 
11.11 ACCESS TO INFORMATION FOR MONITORING 
The study will be conducted in compliance with Good Clinical Practice (GCP). Sponsor will arrange the 
clinical research associates (CRAs) to monitor the conduct of the clinical trial at the investigative sites. 
XBiotech ensures that appropriate monitoring procedures are performed before, during and after the study. 
All aspects of the study are reviewed with the investigator and the staff at a study initiation visit (SIV). 
Prior to enrolling subjects into the study, a XBiotech representative will review theprotocol, eCRFs, 
procedures for obtaining informed consent, record keeping, and reporting of AEs/SAEs with the 
investigator and his/her staff. Monitoring will include on-site visits at regular intervals with the investigator 
and his/her staff as well as any appropriate communications by mail, email, facsimile, or telephone. During 
monitoring visits, the facilities, IP storage area and conditions, eCRFs, subject’s source documents, and all 
other study documentation will be inspected/reviewed by the XBiotech representative. Accuracy and 
protocol compliance will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation. Any resulting discrepancies 
or deviations from the protocol will be reviewed with the investigator and/or his/her staff. Any necessary 
corrections will be made directly to the eCRFs or via queries by the investigator and/or his/her staff. 
Monitoring procedures require that informed consents, adher ence to study protocol and documentation of 
AEs and SAEs and their proper recording be verified. The CRA will make written reports to the Sponsor 
on each occasion when contact with the Investigator is made, regardless of whether it is by phone or in 
person. 
Page 59of 6111.12 STUDY DISCONTINUATION 
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and the reason(s) 
for the termination orsuspension.  The IRB/EC will also be promptly informed and provided with the 
reason(s) for the termination or suspension by the Sponsor or by the Investigator/institution, as specified 
by the applicable regulatory requirement(s).
Page 60of 61REFERENCES
iColeman KM , Gudjonsson JE , Stecher M .  Open -Label Trial of MABp1, a True Human Monoclonal 
Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis.  JAMA Dermatol. 2015 
May;151(5):555- 6. doi: 10.1001/jamadermatol.2014.5391.
iiCarrasco D, Stecher M , Lefebvre GC , Logan AC , Moy R .  An Open Label, Phase 2 Study of MABp1 
Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.  J Drugs Dermatol. 2015 
Jun;14(6):560-4.
iiiKanni T et al. MABp1 Targeting Interleukin -1Alpha for Moderate to Severe Hidradenitis Suppurativa 
not Eligible for Adalim umab: A Randomized Study. J Invest Dermatol. 2017 Nov 9. 
ivBieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med 2008; 358:1483 -94.
vBou-Dargham MJ et al. The Role of Interleukin -1 in Inflammatory and Malignant Human Skin Diseases 
and the Rationale for Targeting Interleukin -1 Alpha. Med Res Rev. 2017 Jan;37(1):180-216.
vi Han et al.  Interleukin -1alpha -induced proteolytic activation of metalloproteinase -9 by human skin. 
Surgery. 2005 Nov;138(5):932 -9.
viiArcher et al. Injury, dysbiosis, and filaggrin deficiency drive skin inflammation through keratinocyte 
IL-1α release. J Allergy Clin Immunol. 2019 Apr;143(4):1426-1443.
viii McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease . J Allergy Clin 
Immunol.2013;131:280 -91.
ixIrvine, A. D., McLean, W. I., & Leung, D. Y. (2011). Filaggrin mutations associated with skin and 
allergic diseases. New England Journal of Medicine ,365(14), 1315-1327.
x Miossec. Anti -interleukin 1α autoantibodies. Ann Rheum Dis 2002; 61: 577 -579.
xi Gallay et al. Characterization and detection of naturally occurring antibodies against IL -1α and IL -1β in 
normal human plasma. Eur Cytokine Network 1991; 2: 329 -338.
xii Suzuki et al. Anti -IL-1α autoantibodies in patients with rheumatic diseases and in healthy subjects. 
Clin Exp Immunol 1 991; 85: 407 -412.
xiii Saurat et al. Anti -IL-1α autoantibodies in humans: characterization, isotype distribution, and receptor-
binding inhibition —higher frequency in Schnitzler’s syndrome (urticaria and macroglobulinemia). J 
Allergy Clin Immunol 1991; 88: 244-256.
xiv Jang et al.  Mass spectrometric quantification of neutral and sialylated N-glycans from a recombinant 
therapeutic glycoprotein produced in Chinese hamster ovary cell lines. Anal. Biochem. 386 (2009) 228 -
236.
xv Müller et al. Autoantibodies to IL -1α  in sera from umbilical cords, children, and adults, and from 
patients with juvenile chronic arthritis. Scand J Rheumatol. 1996; 25 (3): 164 -7.																																																							
Page 61of 61																																																																																																																																																																																		
xvi Svenson et al. Distribution and characterization of autoantibodies to interleukin 1 alpha in norma l 
human sera. Scand J Immunol. 1990: 32 (6): 695 -701.
xviiXu H et al. Increased serum interleukin -6 levels in patients with hidradenitis suppurativa. Postepy 
Dermatol Alergol. 2017 Feb;34(1):82 -84. doi: 10.5114/ada.2017.65626. Epub 2017 Feb 7.
xviiiMontaudié H et al. Interleukin 6 and high -sensitivity C -reactive protein are potential predictive 
markers of response to infliximab in hidradenitis suppurativa. J Am Acad Dermatol. 2017 Jan;76(1):156-
158. doi: 10.1016/j.jaad.2016.08.036.
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,Date: 27 April 2020Janssen Research & Development*
Clinical Protocol
COVID -19 Appendix
Protocol Title
A Phase II, Randomized, Double -Blind, Placebo- Controlled Study of Bermekimab in 
Patients with Moderate to Severe Atopic Dermatitis
Protocol JNJ-77474462ADM2002 ; Phase 2
JNJ-77474462 (bermekimab)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited toJanssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics,
BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland
UC; Janssen Biopharma Inc.;or Janssen Research & Development, LLC. The term “sponsor” is used
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact
Information page that accompanies the protocol.
United States (U S)sites of t his study  will be conducted under US Food & Drug Administration
Investigational New Drug ( IND) regulations (21 CFR Part 312).
Status: Approved
Date: 27April 2020
Prepared by: Janssen Research & Development, LLC
EDMS number: EDMS- RIM-37782 version 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF PROTOCOL
JNJ-77474462
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential. The information is being provided under the assurance that the recipient 
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or 
otherwise .
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-77474462 (bermekimab) Clinical Protocol JNJ-77474462ADM2002
CONFIDENTIAL –FOIA Exem ptions Apply in U.S. 2
Status: Approved ,Date: 27 April 2020COVID -19 APPENDIX
GUIDA NCE ON STUDY CONDUCT DURING THE COVID- 19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study  due to, for example, self-isolation/quarantine by patients and 
study -site personnel; travel restrictions/limited access to public places, including hospitals; study  
site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for 
study-related patient management in the event of disruption to the conduct of the study . This 
guidance does not supersede any local or government guidelines or requirements or the clinical 
judgement of the investigator to protect the health and well -being of patients and site staff. If, at 
any time, a patient’s safety  is considered to be at unacceptable risk, drug product will be 
discontinued, and study  follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, patients will be interviewed to collect safet y data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Patients will also be questioned regarding general 
health status to fulfill any phy sical examination requirement.
Every  effort should be made to adhere to protocol -specified assessments for patients on drug 
product , including follow up. Modifications to protocol -required assessments may be permitted 
via COVID -19 Appendix after consultation between the patient and investigator, and with the 
agreement of the sponsor (see below).
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance. 
If a patient has tested positive for COVID 19, the investigator should contact the sponsor’s 
responsi ble medical officer to discuss plans for drug product and follow -up. Modifications made 
to the study  conduct as a result of the COVID -19 pandemic should be summarized in the clinical 
study  report.
COVID -19 Appendix
JNJ-77474462 (bermekimab) Clinical Protocol JNJ-77474462ADM2002
CONFIDENTIAL –FOIA Exem ptions Apply in U.S. 3
Status: Approved ,Date: 27 April 2020ADDITIONAL ELEMENTS, WHERE APPLICABLE:
Certain protocol -mandated visits to the study  site may not be possible during the COVID -19 
outbreak. Therefore, temporary  measures may be implemented if considered appropriate by 
the sponsor and investigator to maintain continuity of patient care and study integrit y. Certain 
measures, such as those listed below, may be necessary and should be instituted in accordance 
with applicable (including local) laws, regulations, guidelines, and procedures:
oremote (eg, by phone / telemedicine) or in-person, off-site (eg, in-home) interactions 
between site staff (or designees) and patients for study  procedures e.g. those related to 
safet y monitoring / efficacy  evaluation / drug product storage and administration 
(including training where pertinent)
oprocurement of drug product by patients (or designee) or shipment of drug product 
from the study  site directly  to patients for at home administration (including the 
potential for self -administration of drug product )
olaboratory  assessments using a suitabl y accredited local laboratory ; for selected 
measures (eg ,urine pregnancy ), home testing may  be employ ed
oother procedures, eg, imaging, may  be conducted at an appropriate facility
Missed assessments/ visits will be captured in the case report form (CRF) for protocol
deviations. D iscontinuations of drug products and withdrawal from the study  should be 
documented with the prefix “COVI D-19-related ” in the CRF.
oother relevant study  data elements impacted by the pandemic should also be 
documented / labeled as “COVID -19-related” in CRFs and / or other study  systems, 
as directed by detailed sponsor guidance. These may include missed / delay ed / 
modified study  visits / assessments / dosing, and instances where temporary  
measures such as those above are implemented.
The sponsor will evaluat e the totalit y of impact of COVID -19 on collection of key study 
data and additional data analy ses will be outlined in study  SAP(s).
Precaution: for those who may  carry  a higher risk for severe COVID -19 illness (eg ,those 
aged over 65 years), follow guidanc e from local health authorities when weighing the 
potential benefits and risks during participation in the study .